
# Catalogue of Partnering event profiles

## *"HEALTH"*

Contents

## INTRODUCTION OF EVENT

The EU and India, being strategic partners, have renewed their Scientific and Technological Agreement in 2007, as a basis for a continued and intensified cooperation in all fields of research, through the definition of common joint interest and the mutual benefit of access to respective R&D programmes. In the era of rapid globalisation, the EU and India have agreed to significantly increase their science and technology collaboration as underlined at the India-EU Ministerial Science Conference (New Delhi, February 2008). India and the EU conduct research of mutual scientific interest in several fields, and also share the benefits in terms of political and socio economic developments. In this respect, the EU 7TH Framework Programme for Research and Development (FP7) offers an important window of opportunities for S&T partnership, with an already important track record of successful EU-India collaborative research.

As a step forward in EU-India S&T co-operation, the European Commission and the Government of India, Department of Biotechnology have agreed to pool their resources with reciprocal efforts in the areas of food, agriculture and biotechnology research. They recently implemented a coordinated call for EU-India research in the domain of food, health and well-being. In particular, functional foods and the reuse of by products in food processing that were targeted in this cooperation bear the potential of economic growth and putting the economy on a green path towards more sustainability.

The EU-India S&T Cooperation Days 2009 will further contribute to reinforce the EU-India S&T partnership, in various fields of life sciences and biotechnologies research and innovation. A large number of stakeholders from both India and the EU, from public and private sectors, will pave the way for future co-operation via foresight and research policy dialogues, through exchanges of information, networking and mutual training.

The EU-India S&T Cooperation Days will aim at:

1. **Informing** – highlighting the opportunities for cooperation available for European and Indian researchers (FP7 Info Day)
2. **Networking** – providing an opportunity for stakeholders from the EU and India to initiate cooperation in diverse fields of research, and to identify areas of common interest for future collaboration (Networking and Partnering Event)
3. **Training** – encouraging and facilitating participation in EU research, including practical sessions on Framework Programme 7
4. **Research policy analysis and development**- via interactive roundtable discussions to compare respective EU and India research -agendas, -potentials and -needs and to identify possible main lines of mutual interest in view of further collaboration (Round Tables).

### ***EU-India Partnering Event***

The afternoon session of 5th of November is dedicated to an EU-India Partnering Event to stimulate networking between EU and Indian researchers, in order to present together projects under FP7 or ERANET (NEW INDIGO) calls.

EUINEC and EBTC are the main responsible projects for the organisation of the EU-India Partnering Event. The session will be divided into three parts:

- Presentations (10 min) by EU senior researchers on opportunities for EU-India cooperation,
- Presentations (10 min) of Indian researchers of their Organisation,
- Face-to-face meetings between the EU researchers and Indian researchers.

The presentations will be done in 4 parallel sessions: focusing on:

- **Sustainable production and management of biological resources from land, forest and aquatic environment**
- **Life sciences, biotechnology and biochemistry for sustainable non-food products and processes**
- **Fork to farm - Food including seafood, health and wellbeing**
- **Health**

The matchmaking will be done through the *EU-India S&T Cooperation Days* website **www.euindiacoop.org**



This event is funded by the Seventh Framework Programme, European Commission

## ORGANIZATION INVOLVED IN PARTNERING EVENT

**EUINEC -** *European Union and India Enhanced Cooperation Framework for Improved Bilateral Dialogue in the Field of Science and Technology* Funded by the FP7 Capacities programme, EUINEC aims at Improving Scientific and technological cooperation between India and the EU by increasing awareness among Indian and European stakeholders about cooperation opportunities as well as capacity building activities for more successful collaboration. **www.euinec.org**

**EBTC** - *European Business and Technology Centre*

Co-funded by the EC European Commission Aid Programme and based in New Delhi since March 2008, EBTC provides support services to EU companies and researchers wanting to enter the Indian market, with a focus on technologies related to climate change and sustainable development. The Centre is therefore the reference point for the European scientific and business community who wish to strengthen ties with India, as well as for Indian interested in attain a better understanding of the European Union. Through its Biotech Cluster, EBTC will bring European biotechnology and pharma researchers to take part to the event. **www.ebtc.eu**

**New INDIGO -** *Initiative for the Development and Integration of Indian and European Research*

Funded by the FP7 Capacities programme, is a consortium of European and Indian S&T organisations involved in promoting research cooperation between Europe and India. It is intended to strengthen the international dimension of the European Research Area (ERA) by providing a networking platform for Indian and European S&T organisations.

**BIO CIRCLE -** *Creating a CIRCLE by extending the BIO NCP network to Third Countries*

Funded by the FP7 Co-operation programme, aims at fostering S&T co-operation between the EU and Third Countries, including India, in the area of Food, Agriculture, Fisheries and Biotechnologies



This event is funded by the Seventh Framework Programme, European Commission

## INDEX OF PROFILE





This event is funded by the Seventh Framework Programme, European Commission

This event is funded by the Seventh Framework Programme, European Commission

## SECTION HEALTH



This event is funded by the Seventh Framework Programme, European Commission

| PROFILE | |
|---|---|
| **HUNGARY ORGANISATION** | |
| ***Name*** | **BioTalentum Ltd** |
| | andras.dinnyes@iotalentum.hu |
| ***Type*** | SME |
| ***Short description*** | BioTalentum Ltd. is a research start-up company established in 2005. Focus areas of the activities for the company are animal biotechnologies, including stem cell research, transgenic cellular and animal models. The company has a mission of research and development of new animal models and cellular systems for biomedical research and drug testing, and to provide technical services for research teams and pharmaceutical industry based on it's state-of-the-art technological know-how. |
| **PROJECT** | |
| ***Research project*** | ***Human and animal stem cells for regenerative medicine.*** |
| ***Expertise offered*** | stem cell research, pluripotent stem cells, project writing, management |
| ***Requested partner expertise*** | partner are sought with health sector experience, as user of the technology for drug testing and regenerative medicine. |

| PROFILE | |
|---|---|
| **Portugal ORGANISATION** | |
| ***Name*** | **Instituto Gulbenkian de Ciência** |
| | info@igc.gulbenkian.pt |
| ***Type*** | Research center |
| ***Short description*** | The Instituto Gulbenkian de Ciência (IGC) is a leading, international life-science research and graduate training institute, established in 1961 by the Fundação Calouste Gulbenkian, and located in Oeiras, Portugal.<br>Hosting up to 50 small research groups, and several state-of-the art resources and facilities, the IGC functions as a host institution for research programmes in molecular and cell biology, molecular genetics and immunology, evolution and population biology, theoretical and computational biology. |
| **PROJECT** | |
| ***Research project*** | ***The Instituto Gulbenkian de Ciencia - a centre of excellence in biomedical research and graduate education*** |
| ***Description of project*** | Under guidance of a strong, international Scientific Advisory Board, the IGC aims to be a centre of excellence in hypothesis-driven, organism-centred research on the genetic |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | bases of development and evolution of complex systems:<br>Our specific aims are:<br>• to incubate new research leaders, providing state-of-the-art facilities and full intellectual and financial autonomy to pursue research projects;<br>• to maintain and develop international graduate teaching and training programmes;<br>• to promote dialogue with the public about life science;<br>• to foster innovation in the life-sciences, through registration of intellectual property generated by researchers. |
| ***Expertise offered*** | Research programmes at the IGC cover the following areas:<br>• Experimental evolution<br>• Complex genetics<br>• Developmental biology<br>• Infection and immunity<br>• Immunology, inflammation, and auto-immunity<br>• Malaria genetics, cell biology and epidemiology<br>• Mitosis and cytoskeleton<br>• Cell biology and DNA repair<br>• Behavioural neuroscience<br>• Theoretical and computational biology<br>Technological platforms available at the IGC include: biological services (rodents), including specific pathogen free facilities for mice, transgenics facility, zebrafish and Drosophila facilities, confocal, multiphoton and time-lapse microscopy, scanning electron microcopy, high-throughput cell sorting, histology and histopathology, radioactivity facilities, tissue culture laboratories, including P3 lab, DNA sequencing, genotyping and gene expression, bioninformatics services. The IGC runs three PhD programmes, within interdisciplinary biomedical research, neurosciences (in partnershp with the Champalimaud Foundation) and and a doctoral programme for physicinas (in partnership with the Minsitry for Health, the Foundation for Science and Technology, the Champalimaud Foundation and the Gulbenkian Foundation) |
| ***Requested partner expertise*** | Leading research centre in biomedical research or life sciences, with complemantary research interests and technological platforms to those of the IGC, open to collaborations with full intellectal autonomy. |

| **PROFILE** | |
|---|---|
| **ITALY** | **TOP (Transgenic Operative Products) srl** |
| | top@top-mice.com |
| | SME |
| ***Areas of activity*** | preclinical pharmacology; reporter; transgenic animals; in vivo imaging |
| ***Short description*** | TOP srl integrates imaging techniques into the drug discovery process, with the generation of transgenic animals for measuring drug effects on target.<br>We are Spin-off of the University of Milano (Università degli Studi) |
| **PROJECT** | |
| ***Research project*** | ***Generation of reporter mice for the in vivo characterization of drug candidates.*** |
| ***Description of the project*** | TOP srl is generating mice enabling the in vivo measure of cell proliferation, apoptosis, inflammation and other molecular events in all the cells of the animals, enabling real-time, non-invasive characterization of the biologic effects of drugs, nutraceuticals and other alimentary ingredients, or the visualization of potential toxic effects of chemicals and environmental contaminants. |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Expertise offered*** | Generation of reporter systems for in vivo imaging, that display the inducible expression of biomarkers in all the tissues of the mouse, all over the phases of the life cycle, from pregnancy to adult life. |
| ***Requested partner expertise*** | Either a (bio)-pharmaceutical industry interested in speeding up the drug discovery and development pipeline, or a CRO interested in offering to the end customers our models as a powerful tool for preclinical drug research. |

| **PROFILE** | |
|---|---|
| **Italy** | **Lucia Altucci** |
| | lucia.altucci@unina2.it |
| | Professor |
| ***Areas of activity*** | epigenetics, drug discovery, cancer, apoptosis |
| **ORGANISATION** | |
| ***Name*** | Seconda Università di Napoli |
| ***Type*** | University |
| ***Department*** | Patologia generale |
| ***Short description*** | Academia medical research institute |
| **PROJECT** | |
| ***Research project*** | ***Identification and characterisation of epigenetic drugs with anticancer activities*** |
| ***Description of project*** | From a drug discovery approach, identification, biochemical and biological characterisation of drugs able to modulate the action of enzymes that regulate chromatin. Application: Cancer research as well as human diseases |
| ***Expertise offered*** | Biochemical and biological assays |
| ***Requested partner expertise*** | Innovative Drug discovery approaches |

| **PROFILE** | |
|---|---|
| **Finland** | **Kari Airenne** |
| | airenne@uku.fi |
| | Prof. of Molecular Medicine. |
| ***Areas of activity*** | Gene delivery, Gene Therapy, Baculovirus technology, Therapeutic angiogenesis. |
| **ORGANISATION** | |
| ***Name*** | University of Kuopio/A.I. Virtanen Institute |
| ***Type*** | Uniiversity |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Department*** | Department of Biotechnology and Molecular Medicine |
| ***Short description*** | The A. I. Virtanen Institute for Molecular Sciences (AIVI) at Kuopio University is a research institute, one of the six Finnish biocenters and a founder member of the Biocenter Finland consortium. The research profile of AIVI is on molecular medicine of major diseases of high importance for health care, including cardiovascular diseases, neurodegenerative diseases, and metabolism-related diseases. The strong research subareas include: • molecular and cellular mechanisms of the diseases • disease modelling • prevention and therapy of the diseases: gene and cell-based therapy, pharmaceutical intervention • in vitro and in vivo imaging<br>AIVI harbors the Center of Excellence for Research in Cardiovascular Diseases and Type 2 Diabetes and is included in the Nordic Center of Excellence in Neurodegeneration. AIVI holds a status as a Centre of Excellence in Teaching awarded by FINHEEC for the period of 2007 - 2009. Doctoral training and education are carried out at the Graduate School of Molecular Medicine which is a Graduate School combining the expertise of AIVI and the Faculty of Medicine at Kuopio University. AIVI has also a Master's School with two international MSc degree programs. The total number of personnel, including the students, is 220. The proportion of foreigners is 20 %. |
| **PROJECT** | |
| ***Research project*** | ***USE OF BACULOVIRUS AS A VECTOR FOR GENE THERAPY (BACULOGENES, EU FP6 LHSB-CT-2006-037541)*** |
| ***Description of project*** | Baculovirus (BV) Autographa californica multiple nucleopolyhedrovirus is a promising new vector for gene delivery: it is inherently safe and, in addition to insect cells, can efficiently deliver large pieces of DNA into wide range of vertebrate cells; its own genes are poorly expressed in mammalian cells, and it is not known to be associated with any human disease. BV technology has been used for years for producing recombinant proteins, and thus large scale production technology is readily adaptable for the exploitation of gene delivery approaches. In addition, BV vectors can be used efficiently for producing other gene delivery vectors such as lenti and adeno-associated vectors. We have developed several strategies to improve baculovirus-mediated gene delivery into vertebrate cells. The BACULOGENES project aims to develop clinically suitable methods for the development, production, testing and validation of 3rd generation BV vectors for the use in direct gene delivery applications |
| ***Expertise offered*** | Design, modification and generation of baculovirus vectors for gene delivery. |

| | |
|---|---|
| **PROFILE** | |
| **INDIA** | **Nagendrakumar BALASUBRAMANIAN** |
| | srini@indimmune.com |
| | Manager |
| ***Areas of activity*** | Foot and mouth disease research |
| **ORGANISATION** | |
| ***Name*** | Indian Immunologicals Limited |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Type*** | Industry |
| ***Department*** | Research and development |
| ***Short description*** | Indian Immunologicals Ltd. (IIL) was established in 1983. IIL's manufacturing facilities at Hyderabad & Ooty in India are among the largest vaccine producing plants in the world. IIL produces a range of veterinary vaccines such as Foot and Mouth Disease (FMD) vaccine, anti-rabies vaccine, Bacterial vaccines, Canine vaccines and a host of other combined vaccines.<br>IIL pursues not only the mandate of NDDB to provide products and services to enhance the quality of livestock in the country but also use its technological capabilities to the benefit of the people of India. IIL strongly believes that its mission of "immunity made affordable" can be actively pursued only with a sound technology base in modern biotechnology.<br>IIL operates a facility in Ooty to manufacture the vero cell culture rabies vaccine for use in human beings. This plant was set up in 1998 at the specific request of the Government of India so that our country can phase out use of the older and unsafe sheep brain vaccine (also termed nerve tissue vaccine - NTV) with the<br>modern tissue culture vaccine.IIL sells the product under the brand name "Abhayrab" through its network of "Abhay Clinics". IIL is the second company in the world to launch the purified vero cell rabies vaccine (PVRV).The vaccine is sold at very economical price when compared to the brands of multinational companies. The success of Abhayrab and Abhay Clinics emboldened IIL to build a new vaccine facility in Hyderabad to manufacture various other human vaccines such as Diphtheria, Pertussis, Tetanus, Recombinant Hepatitis B, Hepatitis A and Measles. This plant will also produce combination vaccine against these diseases. |
| **PROJECT** | |
| ***Research project*** | ***Studies related to foot and mouth disease transmission, pathogenesis, diagnosis and control strategies*** |
| ***Expertise offered*** | Pathogenesis and transmisson of Foot-and-mouth disease between species, carrier status and control strategies using vaccination |
| ***Requested partner expertise*** | Expertise in vaccine development and identification of carrrier status |

| | |
|---|---|
| **PROFILE** | |
| **INDIA** | **Sameer BAKHSHI** |
| | sambakh@gmail.com |
| | Associate Professor |
| ***Areas of activity*** | Pediatric Cancers |
| **ORGANISATION** | |
| ***Name*** | All India Institute of Medical Sciences |
| ***Department*** | Medical Oncology |
| ***Short description*** | Tertiary care cancer center with all subspecialities of cancer. |
| **PROJECT** | |
| ***Expertise offered*** | Therapy of pediatric hematological and solid malignancies, as well as primary bone and soft tissue sarcomas (for all age groups). |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Requested partner expertise*** | Those interested in the biology of various pediatric cancers. |

| **PROFILE** | |
|---|---|
| **Ireland** | **David BARTON** |
| | david.barton@ucd.ie |
| | Adjunct Associate Professor and Chief Scientist |
| ***Areas of activity*** | Quality, harmonization, validation, assessment, genetic testing |
| **ORGANISATION** | |
| ***Name*** | University College Dublin |
| ***Type*** | University, research center |
| ***Department*** | Molecular Genetics Division |
| ***Short description*** | The National Centre for Medical Genetics provides a comprehensive Medical Genetics Service to the people of Ireland, incorporating Clinical Genetics, Cytogenetics and Molecular Genetics Divisions. The NCMG is actively involved in research into the molecular basis of inherited disorders and is prominent in the area of quality improvement in genetic testing. NCMG scientists have been involved in EU 4th, 5th and 6th Framework projects as partners and coordinators. |
| **PROJECT** | |
| ***Research project*** | ***HARMONIZATION, VALIDATION AND STANDARDIZATION IN GENETIC TESTING*** |
| ***Description of project*** | To continue and expand focused elements of the work of the FP6 EuroGentest Network of Excellence. |
| ***Expertise offered*** | Extensive experience in all aspects of quality assurance in genetic testing, including External Quality Assessment, development of guidelines, development and certification of reference materials and assurance of quality through accreditation and regulation. |

| **PROFILE** | |
|---|---|
| **Germany** | **Michael Beck** |
| | beck@kinder.klinik.uni-mainz.de |
| | Head of Department |
| ***Areas of activity*** | Lysosomal storage disorders, enzyme replacment therapy, clinical trials |
| **ORGANISATION** | |
| ***Name*** | Children`s Hospital, University of Mainz |
| ***Type*** | University |
| ***Department*** | Lysosomal Storage Disorders, Villa-metabolica |
| ***Short description*** | Department, responsible for diagnosis and treatment of patients with a lysosomal storage disorder, adults and children. Includes a laboratory for biochemical diagnosis. Department takes part at various clinical trials. |



This event is funded by the Seventh Framework Programme, European Commission

| PROJECT | |
|---|---|
| *Research project* | ***Diagnosis and treatment of lysosomal storage disorders (LSD)*** |
| *Description of project* | Support in diagnosis, training of physicians and other professionals involved in treatment of LSD patients |
| *Expertise offered* | Expertise in the field of lysosomal storage disorders since 30 years, employees include a neurologist, paediatricians, surgeon and specialized nurses. |
| *Requested partner expertise* | Expertise in metabolic disorders, interest in lysosomal storage disorders. |

| PROFILE | |
|---|---|
| **Italy** | **Guido Bertolini** |
| | giviti@marionegri.it |
| | Head of Clinical Epidemiology Laboratory |
| *Areas of activity* | Critical Care, Epidemiology, Infections |
| **ORGANISATION** | |
| *Name* | Istituto di Ricerche Farmacologiche "Mario Negri" |
| *Type* | Research Center |
| *Department* | GiViTI - Italian Group for the Evaluation of Interventions in Intensive Care Medicine |
| *Short description* | It was established in 1992 as collaborative group bringing together, nowadays, more than 400 Italian Intensive Care Units (ICUs). The Laboratory of Clinical epidemiology (Mario Negri Institute) acts as Coordination centre of GiViTI. The main objective of GiViTI is to produce reliable and general epidemiological data of the Intensive Care Medicine in Italy, in order to develop ad hoc studies in the ICUs addressing more specific issues based on solid scientific evidence. In particular, the assessment of the quality of the healthcare delivered by the ICUs and its impact on patient's outcomes is stated as a main field of investigation. |
| **PROJECT** | |
| *Research project* | ***Promoting patient safety and quality improvement in critical care*** |
| *Description of project* | The leading ideas are:<br>• Self-evaluation is the most powerful means by which an institution can experience a discontinuity of perception that can drive improvement.<br>• Comparing own performance against others is the best way to promote self-evaluation. The project provides ICUs with a method to continuously, easily, rigorously, and confidently measure own performance against others. By joining the project, an ICU will be helped to find out more about its adjusted mortality rate and to analyze the contributing factors. |
| *Expertise offered* | Epidemiology, data collection, system development, statistical analysis, specialistic in critical care |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Requested partner expertise*** | Participation to clinical data collection for international comparison in critical care performances |

| **PROFILE** | |
|---|---|
| **Italy** | **Carla Boitani** |
| | carla.boitani@uniroma1.it |
| | Associate Professor |
| ***Areas of activity*** | Male reproduction system, male fertility, sperm, selenoproteins, spermatogonial stem cells, male germ cell differentiation |
| **ORGANISATION** | |
| ***Name*** | University of Rome "La Sapienza" |
| ***Type*** | University |
| ***Department*** | Histology and medical Embryology |
| ***Short description*** | Sapienza is a public university aimed at excellence in education and research and actively participating in th einetrantional scientific community |
| **PROJECT** | |
| ***Research project*** | ***Sperm chromatin remodeling: role of selenoproteins*** |
| ***Description of project*** | We intend to study the role of the nuclear isoform of GPx4 (glutathione peroxidase) in sperm chromatin condensation/decondensation. In both in vivo and in vitro experiments and using knockout GPx4 mice, we plan to investigate the role of GPx4 in paternal chromatin decondensation after fertilization. |
| ***Expertise offered*** | testis histology, spermatogenic cell isolation, including epididymal sperm, in vitro overexpression of protamines and sperm nuclear proteins, analysis of basic nuclear proteins by western blotting, immunoprecipitation, immunofluorescence and confocal microscopy, FACS analysis |
| ***Requested partner expertise*** | mass spectrometry, structural analysis, enzymatic activity analysis |

| **PROFILE** | |
|---|---|
| **Denmark** | **Kurt Buchmann** |
| | kub@life.ku.dk |
| | Research Centre leader, research school leader, professor |
| ***Areas of activity*** | Disease diagnosis and control, vaccination, fish immunology, |
| **ORGANISATION** | |
| ***Name*** | University of Copenhagen |
| ***Department*** | Veterinary Disease Biology |
| ***Short description*** | Fish diseases and fish immunology research and education |
| **PROJECT** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Research project*** | ***Ontogeny of the fish immune system*** |
| ***Description of project*** | Development of vaccines for aquaculture |
| ***Expertise offered*** | Fish immunology expertise |
| ***Requested partner expertise*** | Fish biology, fish immunology, fish pathology, aquaculture |

| **PROFILE** | |
|---|---|
| **UK** | **Philip Butcher** |
| | admin@sgul.ac.uk |
| | Cellular and Molecular Sciences |
| ***Areas of activity*** | Microbiology Infection Tuberculosis STIs |
| **ORGANISATION** | |
| ***Name*** | St George's University of London |
| ***Type*** | University |
| ***Department*** | Cellular and Molecular Sciences |
| ***Short description*** | A multi-faculty college of the University of London specialising in degrees in Medicine, Biosciences, and Health and Social Care sciences with >5000 students. |
| **PROJECT** | |
| ***Research project*** | ***gene expression in mycobacterium tuberculosis during drug treatment*** |
| ***Description of project*** | The investigation of gene expression reposnses of M.tuberculosis to antibiotics during chemotherapy in humans and during in vitrro models of persistence. |
| ***Expertise offered*** | Microarrays; transcriptomics and genomics; drug target discover through genomics; |

| **PROFILE** | |
|---|---|
| **ITALY** | **Giorgio Carmignoto** |
| | giorgio.carmignoto.unipd.it |
| | Researcher |
| ***Areas of activity*** | Neurobiology |
| **ORGANISATION** | |
| ***Name*** | National Research Council (CNR) |
| ***Type*** | Research organisation |
| ***Department*** | Institute of Neuroscience and Dept of Experimental Biomediacl Sciences- |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | CNR Insitute of Neuroscience, the largest public research organization in Italy. |
| **PROJECT** | |
| ***Research project*** | ***Neuron-glia interactions in brain function and dysfucntion.*** |
| ***Description of project*** | Role of astrocytes in the development brain of hypersynchronous activities, in particular in the epileptic brain. |
| ***Expertise offered*** | Single and double patch-clamp recordings from neurons and astrocytes in brain slcie preparations, field potential recordings and simultaneosu monitoring of calcium signals at laser scanning confocal microscope |

| | |
|---|---|
| **PROFILE** | |
| **Poland** | **Joanna Cichy** |
| | Joanna.Cichy@uj.edu.pl |
| | Associate Professor |
| ***Areas of activity*** | chemoattractants, adhesion molecules, inflammation |
| **ORGANISATION** | |
| ***Name*** | Faculty of Biochemistry, Biophysics and Biotechnology of Jagiellonian University |
| ***Type*** | University |
| ***Department*** | Immunology |
| ***Short description*** | The Faculty of Biochem. Biopphys. and Biotech. (FBBBT) is one of the fifteen faculties of the Jagiellonian University, the second largest University in Poland. The FBBBT is a leading scientific institution in Poland in the fields of biochemistry and biophysics. |
| **PROJECT** | |
| ***Research project*** | ***Role of proteinases in regulating immune responses*** |
| ***Description of project*** | The project goal is to determine the role of metalloproteinases of the ADAM family and neutrophil-derived serine proteinases in shaping immune responses |
| ***Expertise offered*** | skin immunology |
| ***Requested partner expertise*** | biology of proteinases |

| | |
|---|---|
| **PROFILE** | |
| **Hungary** | **Peter Csermely** |
| | csermely@eok.sote.hu |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | professor of network science and biochemistry |
| ***Areas of activity*** | networks, phase transitions, proteome, signalome, metabolome, stress, aging, network modules, game theory, spatial games, evolution |
| **ORGANISATION** | |
| ***Name*** | Semmelweis University, Department of Medical Chemistry, LINK-Group |
| ***Department*** | Department of Medical Chemistry |
| ***Short description*** | The LINK-Group is a bioinformatics group studying the stress responses and the aging process using the analysis of biological networks. We have developed an array of modern network methods to assess the topology and dynamics of networks. These include the analysis of network modules and spatial cooperation games among many others. |

| | |
|---|---|
| **PROFILE** | |
| **U.K.** | **Harish DATTA** |
| | h.k.datta@ncl.ac.uk |
| | Senior Lecturer/Consultant |
| ***Areas of activity*** | Computer-aided drug, organic synthesis, osteoporosis, osteoclast, nanoparticles |
| **ORGANISATION** | |
| ***Name*** | Newcastle University |
| ***Type*** | University |
| ***Department*** | Musculoskeletal Research Group, Institute of Cellular Medicine |
| ***Short description*** | Musculoskeletal Research Group (MRG) is comprised of over a dozen academics sho share broad interest in rheumatological and metabolic bone disease. MGR has all the necessary scientific and technical expertise and laboratory facilities for carrying out cutting edge research. Further information can be obtained on the following website: http://www.ncl.ac.uk/biomedicine/research/groups/musculoskeletal.htm |
| **PROJECT** | |
| ***Research project*** | ***Transcellular disposal of matrix degradation products in an active osteoclast*** |
| ***Description of project*** | The proposed investigation aimed at understnding and modulating osteclast, bone cell which play a crtitical role in the pathogenesis of number of disease, including hypercalcaemia of malignancy, osteoporosis and periarticular destruction seen in rheumatoid arthritis. The proposal utilizes alkyl-capped nanoparticles impregnated into an artificial matrix to study the mechanism of transcellular transport involved in the disposal of degradation products in bone-resorbing osteoclast (OC). The project will focus on the role of relevant calcium channels, pumps and endoplasmic reticulum in the transport of calcium from resorptive vacuole to the basolateral surface of OC. |
| ***Expertise offered*** | We have expertise in the osteoclast isolation, generation and culture, and real-time assay of OC using nanoparticle impregnated artificial matrix. |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Requested partner expertise*** | We require expertise that combines computer-aided molecular design and organic synthesis for the generation of certain mimetics that can be used in the model for modulating OC activity. |

| **PROFILE** | |
|---|---|
| **UK** | **George DAVEY SMITH** |
| | kz.davey-smith@bristol.ac.uk |
| | Scientific Director of ALSPAC & MRC CAiTE Centre (currently on sabbatcial with the South Asia Network for Chronic Disease in Delhi until August 2010) |
| ***Areas of activity*** | epidemiology; genetic epidemiology; epigenetics |
| **ORGANISATION** | |
| ***Name*** | University of Bristol |
| ***Type*** | University |
| ***Department*** | Social Medicine |
| ***Short description*** | The Department of Social Medicine is a leading centre for research and teaching of population health sciences. The primary characteristic of research in the Department is that it is collaborative and multi-disciplinary. |
| **PROJECT** | |
| ***Research project*** | ***How environmental and genetic factors together influence common complex diseases in India*** |
| ***Description of project*** | My programme of research involves cohort studies obtaining biological, social and behavioural data on large groups of people and relating these data to health outcomes. |
| ***Expertise offered*** | Epidemiology, genetic epidemiology |
| ***Requested partner expertise*** | Partners interested in population-based studies at any level, from recruitment through laboratory genetics/epigenetics to analysis. |

| **PROFILE** | |
|---|---|
| **France** | **Jean Delabar** |
| | delabar@univ-paris-diderot.fr |
| | Research Director |
| ***Areas of activity*** | genetic diseases signalling pathways therapeutic modelling |
| **ORGANISATION** | |
| ***Name*** | University Paris Diderot |
| ***Type*** | University, research center |
| ***Short description*** | Laboratory - Functional and adaptative biology |
| **PROJECT** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Research project*** | ***Assessment of therapeutic targeting of Dyrk1a in Down syndrome models*** |
| ***Description of project*** | Down syndrome (DS), the most common genetic source of mental retardation (500000 cases in Europe), is caused by the presence of an extra copy of human chromosome 21 (ie trisomy 21, HSA21). Features of DS are due to overexpression of genes on HSA21 acting either directly or indirectly on the phenotype. Genotype/phenotype correlations have allowed to define candidate regions associated with mental retardation: the smallest region contains 13 genes including a serine threonine kinase Dyrk1a with multiple targets. Mice models of partial trisomy containing Dyrk1a present a number of DS-relevant central nervous system phenotypes including changes in neuronal morphology and functional deficits, especially cognitive impairments in cortical- and hippocampal-dependent learning tasks. These results establish Dyrk1a as a potential target to modify the brain phenotypes.<br>This project will combine expertise in mice genetic, molecular phenotyping, chemical designing, behavioural and electrophysiological analyses. The characterization of an efficient drug, allowing phenotypes (molecular, behavioral, synaptic plasticity) rescue in mice, will be a starting point to design innovative therapeutic strategies for DS. |
| ***Expertise offered*** | animal modelling, molecular analyses, behavioral analyses |
| ***Requested partner expertise*** | pharmaceutical strategies, nanoencapsulation |

| **PROFILE** | |
|---|---|
| **France** | **Barbara DEMENEIX** |
| | demeneix@mnhn.fr |
| | Head of Unit and Department |
| ***Areas of activity*** | Physiology, Endocrinology, Thyroid Hormone |
| **ORGANISATION** | |
| ***Name*** | CNRS/MNHN UMR7221 |
| ***Type*** | Research center |
| ***Department*** | Regulation, Development, Molecular Diversity |
| ***Short description*** | The UMR 7221 is a Joint Research Unit, represented by CNRS and the Muséum National d'Histoire Naturelle.<br>The French National Center for Scientific Research (CNRS) is a government-funded research organization under the administrative authority of France's Ministry of Research. It defines its mission as producing knowledge and making it available to society. CNRS has 31,000 employees (among which 11,700 researchers and 14,400 engineers and technical and administrative staff). Its budget amounts to 2.834 billion euros for the year 2006. The 1190 CNRS service and research units are spread throughout the country and cover all fields of research.<br>The Muséum is a leading research institute in France with expertise in many areas of natural science including chemistry of natural substances, evolution and development, and physiology. The department of Regulations and Development (which is headed by Prof. DEMENEIX) includes five laboratories of which three are affiliated to the CNRS and one to INSERM. The laboratory participating in this consortium is the UMR CNRS Evolution of Endocrine Regulations. This unit addresses the molecular mechanisms of |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | endocrine signalling during development across a number of key species. It comprises 30 permanent staff and 10 students/post-docs. |
| **PROJECT** | |
| ***Research project*** | ***Thyroide Hormone regulation of gene transcription in integrated physiological contexts*** |
| ***Expertise offered*** | Since 1990, Barbara DEMENEIX has held a professorship in the Comparative Physiology Laboratory, a CNRS mixed research unit (http://www.mnhn.fr/rddm/usm501/) within the Natural History Museum in Paris, a higher education and research institution. She was appointed head of the research unit in 1998 and Department head in 2000.<br>Her research focuses on three major axes:<br>1) Addressing the molecular basis of thyroid hormone action during amphibian metamorphosis. Within this context she has developed and applied somatic and germinal transgenic technology. The work has led to the creation of a start up WatchFrog (http://www.watchfrog.fr/) using the germinal transgenic technolog .<br>2) Developing non-viral gene transfer techniques for delivering genes into the central nervous system for both gene therapy and for fundamental research. The methods developed have involved the vectorisation of DNA and siRNA by cationic lipids (Transfectam) and cationic polymers (polyethylenimine). Patents have been taken out for gene therapy applications of both cationic delivery methods, including one covering delivering to neural stem cells in vivo.<br>3) Using in vivo gene delivery techniques to dissect negative regulation of gene transcription by thyroid hormone (TH) and thyroid hormone receptors using the hypothalamic TRH gene as a model. |
| ***Requested partner rexpertise*** | Environnemental contamination ; Brain development; Ageing |

| | |
|---|---|
| **PROFILE** | |
| **India** | **Suman Dhar** |
| | skdhar@mail.jnu.ac.in |
| | Associate Professor |
| ***Areas of activity*** | Drug target identification, DNA replication studies |
| **ORGANISATION** | |
| ***Name*** | Jawaharlal Nehru University |
| ***Type*** | University. Research center |
| ***Department*** | Special Centre for Molecular Medicine |
| ***Short description*** | JNU is a non-profit federal government funded university engaged in teaching in research. Special centre for Molecular Mdicine offers graduate programme in cutting edge areas of Molecular Medicine with a special emphasis in infectious diseases |
| **PROJECT** | |
| ***Research project*** | ***DNA replication and Cell cycle regulation in human malaria parasite Plasmodium falciparum*** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Description of project*** | Characterizing key proteins required for parasite DNA replication (both nuclear as well as apicoplast organelle) since blocking DNA replication will lead to inhibition of parasite proliferation. |
| ***Expertise offered*** | Expression and purification of parasite proteins, generation of antibodies |
| ***Requested partner expertise*** | High throughput screening of drugs or small molecules for parasite specific targets for which assay has been developped, transfection of P. falciparum parasites leading to the expression of fusion proteins and and knock out of parasite genes, development of inducible gene expression system in the parasite. |

| **PROFILE** | |
|---|---|
| **Germany** | **Stefan Dübel** |
| | biotech@tu-bs.de |
| | Director |
| ***Areas of activity*** | scFv, therapeutic antibodies, passive vaccine, phage display, antibody gene libraries, targeted therapy, immuno RNases, affinity proteomics |
| **ORGANISATION** | |
| ***Name*** | Technische Universität Braunschweig |
| ***Type*** | University |
| ***Department*** | Biotechnology |
| ***Short description*** | Looking back on a long lasting tradition, the Department of Biotechnology is one of the divisions of the Institute for Biochemistry and Biotechnology (founded in 1972). In 2002, Prof. Dr. Stefan Dübel joined the Department as its new director, introducing the research focus of Antibody Engineering and Phage Display. In addition, the well established research focus on Biochemical Engineering, led by Prof. Dr. Siegmund Lang and Prof. Dr. Udo Rau, continue its succesful development. Both topics will be combined in a third new focus, Recombinant Protein Production. Spanning a very broad range from basic molecular biology and cell biology to process development in industry contracts, the Department is well equipped to embark into the challenges of cutting egde biotechnology research of the new millennium. |
| **PROJECT** | |
| ***Research project*** | ***Human Antibody Generation and Engineerig*** |
| ***Description of project*** | To make recombinant antibodies to any target in vitro |
| ***Expertise offered*** | Generation, humanisation, improvement of human antibodies |
| ***Requested partner expertise*** | Product development and marketing of human antibodies |

| **PROFILE** |
|---|



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| **Germany** | **H. Einsele** |
| | einsele_h@klinik.uni-wuerzburg.de |
| | Director, Full Professor |
| ***Areas of activity*** | Tumor Genetics, Oncogenic Signalling |
| **ORGANISATION** | |
| ***Name*** | University Hospital Würzburg |
| ***Type*** | University |
| ***Department*** | Internal Medicine II |
| ***Short description*** | The Department of Internal Medicine II of the University Hospital of Wuerzburg runs one of the largest stem cell transplantation programs in Germany (240 autologous and allogenic stem cell transplants in 2009).<br>The department has concentrated on translational research into SCT and immunotherapy supported by a regional network of immunologists, molecular biologists and experts in stem cell research.<br>The Department of Internal Medicine II at the University Hospital of Wuerzburg, is headed by Professor Dr. Hermann Einsele. He is full professor of Internal Medicine and the chairman of the Infectious Disease Working Party of the EBMT, Board member of the European and German Societies of Stem Cell Transplantation, Board Member of the German Lymphoma Net. He published 310 papers and 5 patents.<br>His scientific achievements have been recognized by different national and international awards (e.g. van Bekkum Award of the European Blood and Marrow Transplantation Society).<br>The group is/was involved in different research projects funded by the EU (Manasp, ALLOSTEM, EuroNetLeukemia, NanoII, Marie Curie). Additional funding is received by the DFG (SFB489, SFB 510, TR17, TR 27, SPP1160, single projects), Jose Carreras Foundation, Wilhelm Sander Foundation, Leukemia and Lymphoma Society (USA), NIH, German Cancer Foundation and the BMBF.<br>The group has a large number of international collaborations, which are the basis of these various European Research Networks.<br>The group has long-term, intense collaborative efforts with the several partners in Immunocell (Alejandro Madrigal, Fred Falkenburg, Matthias Edinger, Dirk Busch, Franco Locatelli, Andrea Velardi, Manuel Fernandez) in the field of stem cell transplantation, tolerance induction and adoptive immunotherapy. |
| **PROJECT** | |
| ***Research project*** | ***Myeloma/Lymphoma - Risk stratification/novel drugs, novel targets for Anti-Myeloma Therapy*** |
| ***Description of project*** | Definition of Genetic Risk Factors/new targets for Anti-Myeloma Therapy |
| ***Expertise offered*** | Oncogenic signalling / GEP / Proteomics, High Throughput + Sequencing, siRNA screens |
| ***Requested partner expertise*** | Biobanking / Data collection / Tumor Genetic / Myeloma, Lymphoma, Leukemia experts / Squencing |

**PROFILE**



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| **SPAIN** | **FRANCISCO FERNANDEZ-AVILES** |
| | faviles@secardiologia.es |
| | HEAD OF DEPARTMENT. PROFESSOR OF MEDICINE |
| ***Areas of activity*** | Clinical and interventional activity (echocardiography, electrophysiology, hemodinamic) |
| **ORGANISATION** | |
| ***Name*** | HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON |
| ***Type*** | University |
| ***Department*** | CARDIOLOGY |
| ***Short description*** | University Hospital with a Cardiology Department where every year more than 35000 cardiac patients pass through 7 outpatients clinics, and more than 5000 are admited to the 51-bed cardiology ward and 11-bed coronary care unit. We are served by 4 catheterization laboratories, 2 focus on coronary intervention and 2 on electrophysiology. An imaging centre with 11 echocardiographs produces more than 20000 echos each year. |
| **PROJECT** | |
| ***Research project*** | ***Stem cell therapy applied to the myocardium, heart failure, arrryhtmias and acute coronary syndromes*** |
| ***Description of project*** | These are our expertise areas. The type of research perform is clinical |
| ***Expertise offered*** | We are a centre with good possibilities to recruit patients in clinical trials on the topic described aboved |
| ***Requested partner expertise*** | Companies interested in innovation on the above topics |

| | |
|---|---|
| **PROFILE** | |
| **ITALY** | **Maria FOTI** |
| | maria.foti@unimib.it |
| | Assistant Professor |
| ***Areas of activity*** | Cellular and Molecular Immunology, Functional Genomics |
| **ORGANISATION** | |
| ***Name*** | University of Milano-Bicocca |
| ***Type*** | University |
| ***Department*** | Biotecnology and Bioscience |
| ***Short description*** | The Department of Biotechnology and Bioscience of Milano-Bicocca University was founded in 1999. Researchers in the fields of Biotechnology and Biological Sciences operate in the Department. UNIMIB has wide expertise in Microbiology, Immunology, Cell Biology and Molecular biology. The Department at UNIMIB in Milano is equipped with advanced instrumentation including: High Speed Cell Sorter, Microarray Platform (GeneChip Affymetrix and Illumina), and two photon microscopy. |



This event is funded by the Seventh Framework Programme, European Commission

| PROJECT | |
|---|---|
| *Research project* | ***Molecular Mechanisms involved of Dendritic Cells Activation*** |
| *Description of project* | Dendritic cells (DC) are a special type of leukocytes able to alert the immune system for the presence of infections. They are extremely versatile antigen presenting cells involved in the initiation of both innate and adaptive immunity, but also in the differentiation of regulatory T cells required for the maintenance of self-tolerance. Multiple animal models of infections and autoimmunity are used to investigate how DC can mediate all these diverse and almost contradictory functions.The recent improvements of sequencing technologies, and in particular the publication of the initial version of the human and mouse genome sequences, have opened the field of large-scale functional approaches of biological systems. We employ high-throughput technologies to investigate fundamental aspects of the immune system and their roles in health and disease. In order to identify key cellular genes involved in these processes, we use a transcriptomic approach in which modifications of cellular transcriptome are analysed at several times post-infection. |
| *Expertise offered* | Molecular Biology, Cell Biology, Microarrays and Bioinformatics |

| PROFILE | |
|---|---|
| **Spain** | **Bruno GONZALEZ- ZORN** |
| | bgzorn@vet.ucm.es |
| | Professor |
| *Areas of activity* | Antimicrobial Resistance |
| **ORGANISATION** | |
| *Name* | Universidad Complutense de Madrid (UCM) |
| *Type* | University |
| *Department* | Departamento de Sanidad Animal |
| *Short description* | The UCM is with more than 7000 teachers and 86000 Students the biggest and one of the oldest Universities in Spain. |
| **PROJECT** | |
| *Research project* | ***Molecular Characterization of Antimicrobial Resistance*** |
| *Description of project* | The Antimicrobial Resistance Unit identifes and characterizes from a molecular point of view antimicrobial resistant determinants in bacteria |
| *Expertise offered* | Molecular Microbiology, Molecular Biology, Cellular Microbiology, Microbiology |
| *Requested partner expertise* | Bacterial samples resistant to cliically relevant antibiotics. |



This event is funded by the Seventh Framework Programme, European Commission

| PROFILE | |
|---|---|
| UK | **Liam Good** |
| | jelliott@rvc.ac.uk |
| | Reader in Bacteriology |
| *Areas of activity* | RNA silencing; control of microbes |
| **ORGANISATION** | |
| *Name* | Royal Veterinary College, University of London |
| *Type* | University |
| *Department* | Research Division |
| *Short description* | The RVC is the oldest, largest and only self-governing Veterinary School in the UK. Our mission is to improve the health and welfare of animals. We undertake research of international quality as recognised by our outstanding performance in the recent UK Government run Research Assessment Exercise (90% of our research was categorised as being of international standard). Infection and Immunity research is an area of particular excellence and we integrate lab based scientists with whole animal research and research at the population level. We work on endemic, emerging and exotic disease, particularly those of zoonotic potential and are particularly keen to work with international partners. |
| **PROJECT** | |
| *Research project* | ***RNA recognition and silencing in microbes for infectious disease control*** |
| *Description of project* | Our lab works with small molecular weight ligands and oligomers to recognise and and inhibit RNA in pathogens. Specific projects use biological assay to characterized drug target, understand inhibitor mechanisms, discover novel inhibitors and develope improved diagnostics probes. |
| *Expertise offered* | Biological expertise on bacterial physiology |
| *Requested partner expertise* | Chemistry of oligomer design and delivery to overcome practical problems of drug delivery in vivo. |

| PROFILE | |
|---|---|
| Belgium | **Philippe Goyens** |
| | pgoyens@ulb.ac.be |
| | Head of the Laboratory of Pediatrics |
| *Areas of activity* | Newborn screening; inborn errors of metabolism; nutrition, malnutrition |
| **ORGANISATION** | |
| *Name* | Laboratory of Pediatrics of the Univesité Libre de Bruxelles |
| *Type* | Research center |
| *Department* | Laboratory ofPediatrics, Faculty of Medicine, Université Libre de Bruxelles |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | Neonatal screening of inborn errors of metabolism and hypothyroidism;<br>MS/MS technology; immunochemistry<br>filter paper blood sampling; dried blood spot technology;<br>diagnosis and follow-up of inborn errors of metabolism;<br>diagnosis and prevention of nutritional diseases (including experience in developing countries) |
| **PROJECT** | |
| ***Research project*** | ***- Neonatal screening for inherited metabolic diseases and congenital hypothyroidism***<br>***- Diagnosis and prevention of malnutrition or specific nutritional deficiencies*** |
| ***Description of project*** | - Organisation and follow-up of a neonatal screening program; dried blood spot sampling technology; tandem mass spectrometry and immunochemical techniques<br>- Clinical diagnosis of malnutrition; diagnostic work-up; prevention |
| ***Expertise offered*** | Administrative, clinical and technical |
| ***Requested partner expertise*** | Local partnership for the development of neonatal screening in India<br>Local partnership with teams active in diagnosis and prevention of nutritional problems |

| | |
|---|---|
| **PROFILE** | |
| **Switzerland** | **Sinuhe HAHN** |
| | shahn@uhbs.ch |
| | Research Group Leader |
| ***Areas of activity*** | Non-invasive prenatal diagnosis, preeclampsia, inflammation |
| **ORGANISATION** | |
| ***Name*** | University Hospital Basel |
| ***Type*** | University, research center |
| ***Department*** | Dept. Biomedicine / University Women's Hospital |
| ***Short description*** | Leading health care center and associated biomedical research insitute |
| **PROJECT** | |
| ***Research project*** | ***Biomarkers to detect at-risk pregnancies*** |
| ***Description of project*** | Use of cell-free nucleic acids for non-invasive prenatal diagnosis and quantitative proteomics for detection of new biomarkers |
| ***Expertise offered*** | Analysis of cell-free nucleic acids and complex proteomics |
| ***Requested partner expertise*** | Clinical research experience with preeclampsia and prenatal diagnosis |

| |
|---|
| **PROFILE** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| Errore. L'autoriferimento non è valido per un segnalibro.Errore. L'autoriferimento non è valido per un segnalibro. | **John HAYS** |
| | J.HAYS@ERASMUSMC.NL |
| | Section of Biology and Genetics, University of Verona |
| ***Areas of activity*** | Genetics of respiratory diseases, cardiovascular diseases and type 2 diabetes, Computational genomics |
| **ORGANISATION** | |
| ***Name*** | Section of Biology and Genetics, University of Verona |
| ***Type*** | UNIVERSITY |
| ***Department*** | Section of Biology and Genetics, University of Verona |
| ***Short description*** | Section of Biology and Genetics, University of Verona |
| **PROJECT** | |
| ***Research project*** | Genetics of respiratory diseases, cardiovascular diseases and type 2 diabetes, Computational genomics |
| ***Description of project*** | Genetics of respiratory diseases, cardiovascular diseases and type 2 diabetes, Computational genomics |
| ***Expertise offered*** | Genetics of respiratory diseases, cardiovascular diseases and type 2 diabetes, Computational genomics |
| ***Requested partner expertise*** | Genetics of respiratory diseases, cardiovascular diseases and type 2 diabetes, Computational genomics |

| | |
|---|---|
| **PROFILE** | |
| **Germany** | **Christian Hengstenberg** |
| | christian.hengstenberg@klinik.unir.de |
| | working group leader |
| ***Areas of activity*** | genetic epidemiology, cardiovascular diseases, coronary artery disease, myocardial infarction, dilated cardiomyopathy, risk factors |
| **ORGANISATION** | |
| ***Name*** | University Hospital of Regensburg |
| ***Type*** | University |
| ***Department*** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | Internal Medicine II<br><br>The main duties of a University Hospital are patient care, research and teaching. Each of these areas of responsibility requires highly committed members of staff: We not only provide our patients with the best level of medical care possible at the present time, but contribute to the further development of medicine by internationally acclaimed research and by providing top medical training for doctors and junior scientists. The University Hospital Regensburg has become one of the most modern as well as one of the most efficient hospitals in Germany since its establishment in 1992. |
| **PROJECT** | |
| ***Research project*** | *Globalization of genetic epidemiological findings on cardiovascular diseases* |
| ***Description of project*** | Recent genome-wide association studies revealed several loci linked with coronary artery disease and myocardial infarction, including large replication steps. However, replication efforts were almost exclusively carried out in studies with participants from European descent. Therefore, it is important to expand these efforts to other large ethnicities like Indian populations. In a two step process, replication of European genome-wide association studies could be carried out in Indian case-control samples and Indidan genome-wide association results should be replicated in silico in the existing European studies. |
| ***Requested partner expertise*** | Expertise in genetic epidemiology, phenotyping of cardiovascular diseases, isolation and handling of DNA samples, ethnical standards |
| ***Expertise offered*** | Strong expertise in genetic epidemiology, especially in genome-wide association studies and replication phases. |

| | |
|---|---|
| **PROFILE** | |
| | **Tami Horovitz** |
| | thorovitz@dpharm.com |
| | BD Manager |
| ***Areas of activity*** | Lipid-based drug design and development for stroke, Alzheimer's disease and cancer. Medicinal chemistry and pilot scale production. Preclinical and clinical drug development. The comapany's lead drug candidate is in Phase III clinical development for treatment of acute stroke. |
| **ORGANISATION** | |
| ***Name*** | D-Pharm Ltd |
| ***Type*** | SME |
| ***Short description*** | Speciality biopharmaceutical company developing lipid based drugs mainly for CNS indications and cancer |
| **PROJECT** | |
| ***Research project*** | ***New in vivo models for low through-put screening of drugs for Alzheimer's disease & cancer*** |

This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Description of project*** | Develop new cost effective models for screening drug leads in cancer and neurodegnerative disorders. Current in vivo models in mammals for neurodegeneration and cancer are extremely costly and time consuming. We are interested to find partners that will develop fast in vivo screens in lower eukaryotes. |
| ***Expertise offered*** | We can provide a series of new compounds for screening and to validate new in vivo models for neurodegeneration and cancer. |
| ***Requested partner expertise*** | In vivo model development, in for example, drosophila, c. elegans or zebra fish for rapid & cost effective low through-put drug sceening . |

| **PROFILE** | |
|---|---|
| **Ireland** | **Lokesh Joshi** |
| | Lokesh.Joshi@nuigalway.ie |
| | Professor and Director |
| ***Areas of activity*** | Infectious diseases, cancer, probiotes, neuroscience, biosensors, biomarkers, molecular mimics, HTP tehcnologies, therapeutics, diagnostics, |
| **ORGANISATION** | |
| ***Name*** | Alimentary Glycoscience Research Cluster, National Centre for Biomedical Engineering Sciences, national Unviersity of Ireland Galway. Ireland |
| ***Type*** | Unviersity |
| ***Department*** | National Center for Biomedical Engineering and Sciences |
| ***Short description*** | Alimentary Glycoscience Research Cluster is developing novel glycobiology and glycoehmisty tools to analyze host-pathgen interactions but the members of the group are also active in chronic diseases such as cancer and cardiovascular diseases as well as inflammation and stem cell biology. The Center is also developing HTP technologies for glycoanalysis. Development of new therapeutics and diagnostics are among the main goals of the group. |
| **PROJECT** | |
| ***Research project*** | ***Development of novel HTP glycoanalytical technologies*** |
| ***Description of project*** | The aim of the project is to accelerate the field of glycomics. |
| ***Expertise offered*** | Infectious diseases, cancer, probiotes, neuroscience, biosensors, biomarkers, molecular mimics, HTP tehcnologies, therapeutics, diagnostics, |
| ***Requested partner expertise*** | Complementary expertise to match our expertise in different disease areas and in technology development. |

| **PROFILE** | |
|---|---|
| **INDIA** | **Rajiv JUNEJA** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | juneja@hotmail.com |
| | Consultant<br>Anesthesia, cardiac anesthesia, critical care |
| **ORGANISATION** | |
| ***Name*** | Medanta, The Medicity |
| ***Department*** | Cardiac Anesthesia & Critical Care |
| ***Short description*** | A 450 bedded multispeciality tertiary care facility . It will expand to 1250 beds within the next three years. Apart from healthcare it will provide education , training , medical research and high – end medical diagnostics backed by remarkable infrastructure, futuristic technology across 43 acres |
| **PROJECT** | |
| ***Research project*** | ***1) Prophylaxis and genetic susceptibility of atrial fibrillation following off pump coronary artery bypass graft surgery***<br><br>***2) Effect of tranexamic acid on postoperative bleeding and inflammatory response after open heart valve surgery*** |
| ***Short description*** | 1) Atrial fibrillation (AF) after coronary artery by pass graft surgery (CABG) has incidence of 27-40%. It has predictors, causes postoperative complications and prolonged hospital stay. A genetic predisposition has been proposed. This prospective, randomized, blind study would confirm the hypothesis that post CABG AF has a genetic link and that amiodarone is an effective prophylactic antiarhythmic drug after off pump CABG (OPCAB) ; enabling prophylaxis in genetically predisposed patients who are high risk for CABG especially OPCAB.<br><br>2) Microvascular bleeding after open heart surgery (OHS) is multifactorial. Inflammatory response following cardiopulmonary bypass is (CPB) is well known. Tranexamic acid an antifibrinolytic which reduces post operative bleediing has been proposed to reduce inflammatory response which has not been well studied after CPB. This study proposes confirm the hypothesis that TA reduces inflammatory response post CPB decreasing inflammatory complications after valve surgery in a prospective blind randomized fashion. |
| ***Expertise offered*** | Clinical work. executing the studies, patient follow up, data collection, |
| ***Requested partner expertise*** | Study design, genetic analysis, statistics, funding |

| | |
|---|---|
| **PROFILE** | |
| **India** | **Soumik Kalita** |
| | soumik.kalita@phfi.org |
| | Associate Professor |
| ***Areas of activity*** | Epidemiology; health services research |
| **ORGANISATION** | |
| ***Name*** | South Asia Network for Chronic Disease, Public Health Foundation of India |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Type*** | Research Center |
| ***Short description*** | South Asia Network for Chronic Diseases in India is a collaborative venture between the Public Health Foundation (PHFI) of India and constituent colleges of the Wellcome Trust Bloomsbury Centre for Clinical Tropical Medicine. The Wellcome Trust is UK's largest non-governmental source of funds for biomedical research. The Trust has awarded a £4.5 Million grant to London School of Hygiene and PHFI for setting up a Network for Chronic Disease based in New Delhi over the next five years. The Network comprises of existing research groups based in Delhi, Mumbai, Goa, Chennai and Pondicherry in India; at ICCDR,B in Dhaka, Bangladesh and at Aga Khan University in Karachi, Pakistan . |
| **PROJECT** | |
| ***Research project*** | ***Cardiovascular disease risk in a large Indian Cohort: A household cohort study*** |
| ***Description of project*** | The study aims at conducting a large-scale household cohort study using a cohort in Delhi alongwith existing cohorts run by partner researchers in other parts of India, covering a wide range of social groups and areas in India. Collection of data on common cardiovascular risk factors, prevalence of chronic conditions like hypertension, diabetes, etc and the adequacy of diagnosis in and treatment for these conditions will be seen in the cohort which is would consist of almost 250,000 people. |
| ***Expertise offered*** | The study aims at conducting a large-scale household cohort study using a cohort in Delhi alongwith existing cohorts run by partner researchers in other parts of India, covering a wide range of social groups and areas in India. Collection of data on common cardiovascular risk factors, prevalence of chronic conditions like hypertension, diabetes, etc and the adequacy of diagnosis in and treatment for these conditions will be seen in the cohort which is would consist of almost 250,000 people. |
| ***Requested partner expertise*** | Social Sciences ( qualitative studies) |

| | |
|---|---|
| **PROFILE** | |
| **India** | **Gagandeep KANG** |
| | directorate@cmcvellore.ac.in |
| | Professor of Microbiology |
| ***Areas of activity*** | Enteric viruses and parasites, community based surveillance studies, vaccine trials. |
| **ORGANISATION** | |
| ***Name*** | Christian Medical College |
| ***Type*** | Other |
| ***Department*** | Gastrointestinal Sciences |
| ***Short description*** | The Christian Medical College, Vellore, has always attempted to be a beacon of medical education, care and research in India. It is a medical school with a long standing record of service of patients, training of medical and paramedical staff and in applied and clinical research. The school continues to maintain very high standards in these areas. The major thrust in research has been in areas where the need was perceived to be the greatest such as in leprosy, tropical sprue, polio, diarrhoeal diseases and community |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | health, and more recently in cancer and genetic disorders. |
| **PROJECT** | |
| ***Research project*** | ***Lactobody: Production and delivery of antibody fragments against gastrointestinal pathogens by lactobacilli.*** |
| ***Description of project*** | To generate and express antibody fragments in yeast and lactobacilli to prevent or treat gastrointestinal infections caused by rotavirus and C. difficile. |
| ***Expertise offered*** | Academic clinical trials. |

| | |
|---|---|
| **PROFILE** | |
| **INDIA** | **Poonam Malhotra KAPOOR** |
| | drpoonamaiims@gmail.com |
| | Associated Professor |
| **ORGANISATION** | |
| ***Name*** | All India Institute of Medical Sciences (AIIMS) |
| ***Department*** | Cardiac Anaesthesiology |
| ***Short description*** | AIIMS is an autonomous institution doing clinical, advanced research and acedemics. It caters to over 5,000 open heart surgeries every year both in adults, paediatrics and cathlab procedures. |
| **PROJECT** | |
| ***Research project*** | ***Molecular mechanisms underlying ischaemic preconditioning during CABG: a Baseline Study*** |
| ***Expertise offered*** | An experienced Cardiac Anaesthesiologist, cardiac Biochemist, Cardiologist and cardiac surgeon involved in CABG surgery and collecting the samples and data for clinical research in AIIMS, Delhi |
| ***Requested partner expertise*** | Expertise needed for improving study design, statistical analysis, multicentric trials of similar stidy with the european community and sanction of funds. |

| | |
|---|---|
| **PROFILE** | |
| **INDIA** | **Dr. Bakulesh KHAMAR** |
| | bmk@cadilapharma.co.in |
| | Executive Director - Research |
| **ORGANISATION** | |
| ***Name*** | Cadila Pharmaceuticals Ltd |
| ***Type*** | Industry |
| ***Department*** | Research and Development |
| ***Short description*** | Manufacturing:<br>Over the last five decades, it has been developing and manufacturing pharmaceutical products. An integrated healthcare over 50 therapeutic areas that include cardiovascular, |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The company focuses on providing high quality, appropriately priced products to its customers and supports all these with dedicated customer service.<br>The company has state-of-the-art manufacturing facilities conforming to the most stringent international cGMP norms vis-à-vis WHO-GMP, WHO, Geneva (GDF site for Anti- TB), TGA Australia (PIC/S), USFDA, UK- MHRA, MCC-South Africa, ISO 9001 and ISO 14001. Spread over hundred forty (140 acers) acres of land.<br>The company's two API units at Ankleshwar manufacture a wide-range of APIs and intermediates.<br>The second manufacturing facility at Samba, near Jammu, started its commercial operations in August 2006.<br>R&D activity:<br>The company has one of the best Research and Development (R&D) setups in India, manned by more than three hundred eighty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering. The company also participates in Public-Private partnerships for developing diagnostic, preventive and curative pharmaceutical and diagnostic products.<br>Cadila Pharmaceuticals is the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed four more INDs with USFDA. Of the five INDs filed, one is for pulmonary tuberculosis; the trial is supported by Department of Biotechnology, Govt. of India. The rest four are for various types of cancers, e.g., Lung Cancer, Prostrate cancer, Bladder Cancer and Melanoma. Thus all the INDs are for providing solutions to major global health care problems. The clinical trials on Prostrate cancer, Lung cancer and Bladder cancer are supported by Department of Science and Technology to encourage innovations.<br>World's first from Cadila Pharmaceuticals<br>• Polypill for cardiovascular prevention (Polycap)<br>• Anti-TB drug with Bio-enhancer ( Risorine)<br>• Sparfloxacin Eye Drops (Scat Eye Drops)<br>• parenteral formulation of Rabeprazole (Rabeloc I.V.)<br>• Probiotic combined with anti-infective agent (Symbiotic)<br>• manufacturer of a unique immunomodulator (IMMUVAC)<br>• whole blood, rapid HIV detection kit (NEVA HIV) |

| **PROFILE** | |
|---|---|
| **India** | **INSHAD KHAN** |
| | inshad@yahoo.com. iakhan@iiim.res.in |
| | Scientist |
| ***Areas of activity*** | Clinical Microbiology, Molecular biology |
| **ORGANISATION** | |
| ***Name*** | Indian Institute of Integrative Medicine |
| ***Type*** | Research center |
| ***Department*** | Clinical Microbiology |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | Indian Institute of Integrative Medicine, Jammu (IIIMJ) is a multi- disciplinary organization having the facility for advance product Chemistry, Pharmacology, Biotechnology and Botanical Sciences. The major areas of research include standardizing the agro technology of Medicinal and Aromatic plants, their propagation techniques , isolation of active fraction/s and single molecules from such plants. Screening for the bioactivity of these plants extracts/ fractions and molecules and exploiting the microbes for useful reactions. IIIMJ is also involved in the screening of microbial wealth from niche areas of North West Himalayas for the isolation and application of useful enzymes for industrial processes. Several enzymes like lipase/esterase, peroxides, oxido-reductase, nitrilase and glycosidase have been identified and their functional properties established. We have a large repository of natural as well as synthetic compounds which are being screened for various activities using insilico approach. |

| **PROFILE** | |
|---|---|
| **The Netherlands** | **Gerrit Koopman** |
| | koopman@bprc.nl |
| | Unit Head Cell Mediated Immunology |
| ***Areas of activity*** | HIV, vaccine, therapy |
| **ORGANISATION** | |
| ***Name*** | Biomedical Primate Research Centre |
| ***Type*** | Research center |
| ***Department*** | Virology |
| ***Short description*** | The Biomedical Primate Research Centre (BPRC) in the Netherlands has a large colony of rhesus macaques and common marmosets for biomedical research.The department of virology has extensive experience in the use of non-human primates for pre-clinical evaluation of HIV vaccine candidates as well as testing of anti-viral strategies. Infection models of SIV or HIV/SIV recombinant viruses in rhesus macaques have been established and extensively used. In addition, an anti-retroviral treatment model was set up in both SIV infected and SHIV infected rhesus macaques. In this model both therapeutic vaccination strategies as well as gene therapy studies with HIV inhibitory genes were performed. |
| **PROJECT** | |
| ***Research project*** | ***Pre-clinical evaluation in non human primates of vaccines as well as therapies directed against HIV*** |
| ***Description of project*** | We seek collaborations both in the area of HIV vaccine development as well as the evaluation of new virus inhibitory strategies, either in the form of anti-viral or immunomodulatory drugs or as gene therapy. The BPRC can offer appropriate non human primate animal models for pre-clinical evaluation of these strategies, including immunological and virological assays for further characterization of the responses. |
| ***Expertise offered*** | The virology department can offer a variety of cellular and humoral analysis, specifically optimized for the monkey models used. These involve IFNgamma, IL2, IL4 ELISpot assays, intracellular cytokine staining assays, multiparameter FACS analysis (11 colours), Luminex multiplex (23 cytokines), virus neutralization assays as well as whole blood |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | analysis of NK cell and monocyte phenotype and function. In addition, analysis at the molecular level, immuno histochemistry and analysis of a full spectrum of haematology and clinical chemistry parameters is available. |
| ***Requested partner expertise*** | We seek partners that have developed new HIV vaccine candidates , or anti-viral strategies that have been pre evaluated in vitro as well as in small animal models and are under consideration for subsequent clinical development. |

| **PROFILE** | |
|---|---|
| **France** | **Eric Kremer** |
| | eric.kremer@igmm.cnrs.fr |
| | PI, Director of Research |
| ***Areas of activity*** | disorders of the CNS, virology, gene transfer, Adenoviridae receptors, intracellular trafficking & vectorology |
| **ORGANISATION** | |
| ***Name*** | CNRS |
| ***Type*** | research institute |
| ***Department*** | Adenoviridae: receptors, trafficking & vectorology |
| ***Short description*** | Public research institute linked to the University of Montpellier |
| **PROJECT** | |
| ***Research project*** | ***Gene transfer vectors to target neurons in vivo*** |
| ***Description of project*** | Developping and testing gene transfer vectors to understand and treat neurodegeneration |
| ***Expertise offered*** | Biochemistry, cell biology, immunology, virology, gene transfer |
| ***Requested partner expertise*** | Open to numerous options in the fields of neurobiology, cell biology and immunology |

| **PROFILE** | |
|---|---|
| **Poland** | **Grzegorz Kruszynski** |
| | gkruszynski@op.pl |
| | assistant |
| ***Areas of activity*** | esearch, health sciences, clinical skills exchange |
| **ORGANISATION** | |
| ***Name*** | Poznan University of Medical Sciences |
| ***Type*** | University |
| ***Department*** | Department of Perinatology and Gynecology |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | One of the best polish Medical Universities. Our Department is an active scientific and clinical center. We participate in a few international research trials. |
| **PROJECT** | |
| ***Research project*** | ***Prediction of hypertensive disorders in pregnacy.*** |
| ***Description of project*** | Digital pulse amplitude tonometry and endothelial function evaluation in pregnancy complicated with arterial hypertension |

| | |
|---|---|
| **PROFILE** | |
| **Sweden** | **Pierre Lafolie** |
| | pierre.lafolie@karolinska.se |
| | Head |
| ***Areas of activity*** | Clinical research, education |
| **ORGANISATION** | |
| ***Name*** | Karolinska Trial Alliance, Karolinska University Hospital |
| ***Type*** | Other |
| ***Department*** | Karolinska Trial Alliance |
| ***Short description*** | Karolinska Trial Alliance (KTA) is a unit within the Karolinska University Hospital with the aim to facilitate the conduct of clinical research within the Stockholm region. The following services are offered:<br>– Clinical trials at our own research unit (fas1)<br>– The administration required to conduct and quality-assure clinical trials<br>– Advice and training on how to conduct clinical trials<br>– Tools and advice for managing the financial and legal aspects of clinical trials<br>– Coordination with healthcare<br><br>The Karolinska Trial Alliance is a parter in several EU-funded projects, namely European Clinical Research Infrastructures Network (ECRIN), European Medicines Research and Training Network and Pharmaceutical Medicines Training Program (Pharmatrain). |

| | |
|---|---|
| **PROFILE** | |
| **Austria** | **Irene Lang** |
| | irene.lang@meduniwien.ac.at |
| | Professor of Vascular Biology |
| ***Areas of activity*** | vascular biology, interventional cardiology, pulmonary hypertension |
| **ORGANISATION** | |
| ***Name*** | Medical University of Vienna |
| ***Type*** | University |
| ***Department*** | Cardiology |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| *Short description* | an excellent internationally oriented cardiovascular institute |
| **PROJECT** | |
| *Research project* | ***Mechanisms of vascular occlusion*** |
| *Description of project* | I am studying gene expression in the vascular wall, and the impact of thrombosis in vascular remodeling |
| *Expertise offered* | I am studying gene expression in the vascular wall, and the impact of thrombosis in vascular remodeling |
| *Requested partner expertise* | facility with experienced translational researchers, vascular biologist, clinical scientist |

| | |
|---|---|
| **PROFILE** | |
| **The Netherlands** | **Jan LANGEVELD** |
| | jan.langeveld@wur.nl |
| | sr scientist |
| *Areas of activity* | infections, prions |
| **ORGANISATION** | |
| *Name* | Central Veterinary Institute of WageningenUR |
| *Type* | Research center |
| *Department* | Bacteriology & TSEs |
| *Short description* | private veterinary health institute with public eyemark; in charge as NRL and statutory testing & test developments including vaccines. |
| **PROJECT** | |
| *Research project* | ***Diagnostics and basic research of prion diseases like BSE, scrapie and CJD*** |
| *Expertise offered* | protein biochemistry, molecular biology, epidemiology, risk assesments |
| *Requested partner expertise* | Prion field |

| | |
|---|---|
| **PROFILE** | |
| **France** | **Vincent LAUDET** |
| | Vincent.Laudet@ens-lyon.fr |
| | Director of the IGFL |
| *Areas of activity* | Endocrine Disruptors, Nuclear Hormone Receptors, Zebrafish |
| **ORGANISATION** | |
| *Name* | Ecole Normale Supérieure de Lyon |
| *Type* | University |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Department*** | Institut de Génomique Fonctionnelle de Lyon |
| ***Short description*** | The IGFL is a research department devoted to functional genomics at the ENS de Lyon. We are interested in using molecular genetics, evolutionary sciences and developmental biology to tackle a small number of relevant biological questions. Among them is the role played by nuclear receptors and their ligands, among which are the endocrine disruptors found in food. We use various model systems (zebrafish, mouse, cell cultures etc…) as well as bioinformatics to study these molecules in an integrated context. |
| **PROJECT** | |
| ***Research project*** | ***Detection of endocrine disruptors in food using specific model systems*** |
| ***Description of project*** | Detection of toxic compounds using an original biological systems such as: (i) transgenic zebrafish; (ii) transgenic mouse; (iii) male sperm cells differentiation system in culture |
| ***Expertise offered*** | Ability to develop relevant biological systems to detect endocrine disruptors (or more generally toxic compounds) present in food and better understand their mechanisms of action. |
| ***Requested partner expertise*** | Risk assessment, Epidemiological and Ecotoxicological competences |

| | |
|---|---|
| **PROFILE** | |
| **FRANCE** | **Pierre-Marie LLEDO** |
| | pmlledo@pasteur.fr |
| | Head of the laboratory |
| ***Areas of activity*** | Olfaction; Aging; Regeneration; Neurodegenerative deseases. |
| **ORGANISATION** | |
| ***Name*** | Pasteur Institute |
| ***Type*** | other |
| ***Department*** | Neuroscience |
| ***Short description*** | The Pasteur Institute's mission is to contribute to the prevention and treatment of emerging diseases through research, education, and public health activities. Research concerning emerging diseases, including Neurosciences, represents the largest Institute's effort (representing about 50% of the total activity). The Institut Pasteur is recognized worldwide as a leader research institution in Biomedical research. The Institute is also very open internationally and has and numerous exchanges with European and non-European countries. A students' and post-doc's association also organizes technical short courses on cutting edge topics. Every year, over 800 trainees belonging to 60 different nationalities come for short or longer periods to perfect their skills in the institute's laboratories. With its 12 departments organized in 130 laboratories, the Institute devotes about 40 % of its research activity to emerging diseases that includes neurological diseases. It is equipped with high quality technical platforms that are fully open to all researchers on the campus. |
| **PROJECT** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Research project*** | ***Regenerating the sense of smell*** |
| ***Description of project*** | Adult neurogenesis is interesting for two reasons that to some degree are unrelated. In the context of cognitive functions, making new neurons for mature circuits is important. At the same time, adult neurogenesis is a model system for investigating central questions in applied stem cell biology. To address these questions we have chosen the adult olfactory bulb since it undergoes constant remodeling by way of integrating new interneurons. We propose a combined effort to analyze the molecular mechanisms responsible for the specification of adult-generated interneurons and their physiological properties, in order to understand their unique contribution to information processing. In particular, we seek to address the following questions: Is there anything special about the new neurons besides their later birth? How could they possibly contribute to brain functions? What are the molecular mechanisms regulating their turnover? Our current research tackles a series of fundamental questions that will create new knowledge on the basic mechanisms and functions of adult neurogenesis involved in olfaction. |
| ***Expertise offered*** | Neurophysiology; Behavior; Neural stem cells. |
| ***Requested partner expertise*** | Computational Neurosciences; Behavior; In vivo Electrophysiology. |

| **PROFILE** | |
|---|---|
| **France** | **Camille LOCH** |
| | camille.locht@pasteur-lille.fr |
| | Research Director |
| ***Areas of activity*** | infection, tuberculosis, vaccines, diagnostics, drugs |
| **ORGANISATION** | |
| ***Name*** | Inserm / Institut Pasteur de Lille |
| ***Type*** | Research center |
| ***Department*** | Infection and Immunity |
| ***Short description*** | Private/public research organization involved in medical research on infection, cancer, cardio-vascular and neurodegenerative diseases |
| **PROJECT** | |
| ***Research project*** | ***Bacterial respiratory infections*** |
| ***Description of project*** | The laboratory works on bacterial respiratory infections, in particular tuberculosis and pertussis, in order to better understand the molecular and cellular mechanisms of the pathogenesis with the hope to be able to design new vaccines, diagnostics and drugs |
| ***Expertise offered*** | molecular biology, biochemistry, bacteriology, immunology, genomics, proteins, animal models |
| ***Requested partner expertise*** | animal models, clinical immunology, microbiology |



This event is funded by the Seventh Framework Programme, European Commission

| PROFILE | |
|---|---|
| Spain | **Josè López-Miranda** |
| | jlopezmir@uco.es |
| | Professor of Medicine. Department of Internal Medicine. Lipid and Atherosclerosis Unit. Reina Sofia University Hospital Scholl of Medicine. University of Córdoba. |
| ***Areas of activity*** | Nutrigenomics, metabolic syndrome, adipose tissue, gene expression, Mediterranean diet, insulin resistance, postprandial lipaemia, endothelial function. |
| **ORGANISATION** | |
| ***Name*** | Reina Sofía University Hospital. IMIBIC. University of Cordoba |
| ***Type*** | University, research center |
| ***Department*** | Internal Medicine |
| ***Short description*** | The Institute for Biomedical Research (IMIBIC) is the integrative entity which carriers out all the biomedical research in Córdoba. Our group, Lipids and Atherosclerosis Unit, is integrated in the Reina Sofía Iniversity Hospital , wich is a member of IMIBIC. |
| **PROJECT** | |
| ***Research project*** | ***Nutrigenomic of obesity and metabolic syndrome*** |
| ***Description of project*** | Now there are multiple evidence suggesting that the metabolic syndrome (MetS) is an adiposopaty (peripheral adipose tissue dysfunction) that occurs during the postprandial state. A recent and emerging concept in the pathogenesis of adipose tissue dysfunction in MetS is the presence of increased oxidative stress associated with a dysfunction of mitochondria in obesity adipocyte all responses that trigger molecular and cellular inflammatory pathways which ultimately give rise to the insulin resistance syndrome. OBJECTIVE: To investigate if long-term consumption of a MUFA-rich diet determines a reduced adipocyte oxidative stress than after a diet rich in saturated fat or following low-fat diets enriched with long chain PUFA n-3. |
| ***Expertise offered*** | Our group has had an important participation in development of nutrigenomics, science that has emerged conceptually in the last ten years thanks to studies similar to ours.<br>In the last 5 years the scientific production' group has consisted in 54 original papers in journals of great impact (Am J Clin Nutr; J Mol Endocrinol; J Lipid Res, J Clin Endocrinol Metab, Atherosclerosis, Ann Int Med , Diabetes, Diabetologia, Diabetes Care) with a cumulative impact in the past 5 years to 204.5 points.<br>During this period we have received continued funding, including participation in a project of the European Union (FP6: LIPGENE: "Diet, Genes and Metabolic Syndrome") related to the proposal. Also, our group has been coordinator of study related with the effect of diet on postprandial lipoprotein metabolism in patients with metabolic syndrome. Finally, this group has experience in analysis of gene expression and identification and characterization of relevant gene involved in hormonal secretion and expressed in adipose tissue. |
| ***Requested partner expertise*** | Nutrigenomic of obesity and metabolic syndrome |



This event is funded by the Seventh Framework Programme, European Commission

| PROFILE | |
|---|---|
| Italy | **Giovanni MALERBA** |
| | giovanni.malerba@univr.it |
| | Assistant Professor |
| ***Areas of activity*** | Genetics of respiratory diseases, cardiovascular diseases and type 2 diabetes, Computational genomics |
| **ORGANISATION** | |
| ***Name*** | Section of Biology and Genetics, University of Verona |
| ***Type*** | University |
| ***Department*** | Mother and Child, and Biology – Genetics |
| ***Short description*** | Over the years the studies of the group focused on genetic analysis of both Mendelian (Cystic Fibrosis and related disorders, Osteogenesis Imperfecta, and others) and complex diseases (asthma, respiratory diseases, cardiovascular diseases, osteoporosis, multiple sclerosis, diabetes and others). Multifactorial diseases are predominantly studied at the DNA level in order to identify linkage or association of DNA polymorphisms with the variability of phenotype. |
| **PROJECT** | |
| ***Research project*** | ***A comprehensive gene-gene and gene-environmental study of socially important diseases in India and the EU*** |
| ***Description of project*** | Genome wide analysis has been conducted for several important diseases in large populations, but results explain a small part of the estimated genetic contribution. A possible reason is gene-environment interactions are not generally considered. Furthermore, there is little information provided on the functional role of identified genes.<br>Several studies have recently shown that some gene polymorphisms are associated with diseases that were supposed not to be directly associated one with the other. We aim to identify 2 important common diseases in India and UE that might share common genetic susceptibility factors.<br>We aim to correlate disease onset and also co-morbidities between diseases and their complications, and identify potential prognostic markers by a functional analysis of selected DNA polymorphisms and a global gene expression profiling. Predictive models for use by epidemiologists and clinicians will be developed. |
| ***Expertise offered*** | The group is equipped with instruments that permit to complete molecular and computational analyses at each stage of the study. Several studies are devoted to gene expression analysis (genome-wide or group of specific genes) of several tissues mainly related to cardiovascular system. Computational and bioinformatic analysis is performed through several dedicated computer programs and by the development and implementation of new algorithms. The group also manages a multi-user database storing information for thousands of individuals. Several programs have been prepared to simplify several operations such as retrieval of relevant information, showing a descriptive statistic of selected samples, output of data in several formats, input of genotype data. The group has the full range of laboratory equipment for medical genetics, including several thermal cyclers, real-time PCR, image analysis, electrophoresis and DGGE. |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Requested partner expertise*** | The partners should be able to collect biological samples from patients with the diseases that will be investigated, as well as from healthy controls. Partners should compute epidemiological analysis able to integrate genetic information . Disease information, environmental and lifestyle data should be available or collected to provide a comprehensive description of gene-environment interactions related to each disease. |

| **PROFILE** | |
|---|---|
| **Italy** | **Patrizia Mecocci** |
| | mecocci@unipg.it |
| | Director of the University Institute and the Hospital Clinic of Geriatrics |
| ***Areas of activity*** | Aging, Alzheimer disease, cognitive impairment, frailty, disability, elderly, nutrition, vitamins |
| **ORGANISATION** | |
| ***Name*** | University of Perugia |
| ***Type*** | University |
| ***Department*** | Section of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine |
| ***Short description*** | Geriatric department with facilities for the study of cognitive function, disability, osteoporosis |
| **PROJECT** | |
| ***Research project*** | ***Effect of nutrition on healthy aging, cognitive function, frailty*** |
| ***Description of project*** | Evaluation of nutritional, cognitive stus and study of biological markers of age related diseases |
| ***Expertise offered*** | Memory clinic, geriatric hospital ward, biochemistry laboratory |
| ***Requested partner expertise*** | Expertise in the evaluation of elderly and interest in aging research |

| **PROFILE** | |
|---|---|
| **INDIA** | **Yatin MEHTA** |
| | yatinmehta@hotmail.com |
| | Consultant |
| | Anesthesia, cardiac anesthesia, critical care |
| **ORGANISATION** | |
| ***Name*** | Medanta, The Medicity |
| ***Department*** | Cardiac Anesthesia & Critical Care |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | A 450 bedded multispeciality tertiary care facility . It will expand to 1250 beds within the next three years. Apart from healthcare it will provide education , training , medical research and high – end medical diagnostics backed by remarkable infrastructure, futuristic technology across 43 acres |
| **PROJECT** | |
| ***Research project*** | ***1) Prophylaxis and genetic susceptibility of atrial fibrillation following off pump coronary artery bypass graft surgery***<br><br>***2) Effect of tranexamic acid on postoperative bleeding and inflammatory response after open heart valve surgery*** |
| ***Short description*** | 1) Atrial fibrillation (AF) after coronary artery by pass graft surgery (CABG) has incidence of 27-40%. It has predictors, causes postoperative complications and prolonged hospital stay. A genetic predisposition has been proposed. This prospective, randomized, blind study would confirm the hypothesis that post CABG AF has a genetic link and that amiodarone is an effective prophylactic antiarhythmic drug after off pump CABG (OPCAB) ; enabling prophylaxis in genetically predisposed patients who are high risk for CABG especially OPCAB.<br><br>2) Microvascular bleeding after open heart surgery (OHS) is multifactorial. Inflammatory response following cardiopulmonary bypass is (CPB) is well known. Tranexamic acid an antifibrinolytic which reduces post operative bleediing has been proposed to reduce inflammatory response which has not been well studied after CPB. This study proposes confirm the hypothesis that TA reduces inflammatory response post CPB decreasing inflammatory complications after valve surgery in a prospective blind randomized fashion. |
| ***Expertise offered*** | Clinical work. executing the studies, patient follow up, data collection, |
| ***Requested partner expertise*** | Study design, genetic analysis, statistics, funding |

| | |
|---|---|
| **PROFILE** | |
| **Italy** | **Jacopo Meldolesi** |
| | meldolesi.jacopo@hsr.it |
| | Professor of General Pharmacology |
| **ORGANISATION** | |
| ***Name*** | Vita-Salute San Raffaele University |
| ***Type*** | University |
| ***Department*** | Neurscience |
| ***Short description*** | University prestigeous especially in Medicine and Biomedical Research. |
| **PROJECT** | |
| ***Research project*** | ***Gene expression in the brain in health and disease.*** |
| ***Description of project*** | Exploration of the transcriptional, post-transcriptional and cellular mechanisms that account for the specificicity of neurons and astrocytes; role of the interactions between |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | these two types of cells; alterations of the above processes in the diseased brain. |
| ***Expertise offered*** | Wide experience and high tech in biomedical reasearch |
| ***Requested partner expertise*** | experience in the molecular and cellular study of single brain diseases |

| **PROFILE** | |
|---|---|
| **HUNGARY** | **Béla MELEGH** |
| | bela.melegh@aok.pte.hu |
| | Chairperson |
| ***Areas of activity*** | Biobanking, rare diseases, population genetics |
| **ORGANISATION** | |
| ***Name*** | University Pécs |
| ***Type*** | University |
| ***Department*** | Department of Medical Genetics |
| ***Short description*** | Largest university in Hungary with wide spectrum of research, teaching and diagnostic activity. |
| **PROJECT** | |
| ***Research project*** | ***Rare disease research, biobanking*** |
| ***Short description*** | We are the National center for the rare diseases with strong EU networking. |
| ***Expertise offered*** | Clinical and molecular genetics; diagnostics and research. As a member of the Science Advisory Board of the Biobanking and Biomolecular Resources Infrastructure (FP7, http://www.bbmri.eu); my goals include to find partners in India. |
| ***Requested partner expertise*** | Clinical and/or medical genetics, biobanking. |

| **PROFILE** | |
|---|---|
| **ESTONIA** | **Andres Metspalu** |
| | geenivaramu@geenivaramu.ee |
| | M.D.,Ph.D. Professor and Director of The Estonian Genome Project, University of Tartu |
| **ORGANISATION** | |
| ***Name*** | Estonian Genome Project, University of Tartu |
| ***Type*** | University – Research Center |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | The Estonian Genome Project is a research institute of University of Tartu. The Estonian Genome Project, University of Tartu carries out the Estonian Genome Project with the goal to create a database (biobank) of health, genealogy and genomic data from 50 000 individuals. The database will make it possible to carry out research to find links between genes, environmental factors, lifestyles and common diseases or other traits. In October 2009 the gene bank contains the data of 38 000 gene donors. With the increase of the number of gene donors it will be suitable for many genetic epidemiological studies |
| **PROJECT** | |
| ***Research project*** | ***Estonian Genome Project*** |
| ***Short description*** | The Estonian Genome Project, University of Tartu carries out the Estonian Genome Project with the goal to create a database (biobank) of health, genealogy and genomic data from 50 000 individuals. |
| ***Expertise offered*** | The database will make it possible to carry out research to find links between genes, environmental factors, lifestyles and common diseases or other traits.<br>In October 2009 the gene bank contains the data of 38 000 gene donors. With the increase of the number of gene donors it will be suitable for many genetic epidemiological studies. |
| ***Requested partner expertise*** | Biobanks related research and data exchange |

| | |
|---|---|
| **PROFILI** | |
| **Czech Republic** | **Jaroslav Michalek** |
| | jmichalek@fnbrno.cz |
| | Head of Department |
| ***Areas of activity*** | cancer, immunology, molecular biology, biotechnology, clinical trials |
| **ORGANISATION** | |
| ***Name*** | Masaryk University |
| ***Type*** | University |
| ***Department*** | University Cell Immunotherapy Center |
| ***Short description*** | University Cell Immunotherapy Center (UCIC) focus on translational research in the field of anti-cancer vaccines (3 academic investigator driven phase II trials in glioblastoma, melanoma and myeloma) based on dendritic cells and adoptive T cell transfer. Another translational research is focussed on mesenchymal stromal cells and therapy of GVHD, Crohn´s disease and other immune-mediated disorders. GMP clean rooms are an integral part of UCIC. |
| **PROJECT** | |
| ***Research project*** | ***Cell based therapy of cancer and autoimmune disorders involving dendritic cell based immunotherapy, adoptive T cell transfer and mesenchymal stromal cells.*** |
| ***Description of project*** | Phase I/II clinical trials for treatment of patients with different cancer types using adoptive T cell transfer and dendritic cell based vaccination in combination with conventional anti-cancer therapy.<br>Mesenchymal stromal cell (MSC) therapy of autoimmune disorders as well as usage of |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | regenerative potential of MSC in diabetic foot. |
| ***Expertise offered*** | Clinical trial organisation and expertise, patient recruitment, vaccine manufacturing, immunomonitoring, molecular biology techniques |
| ***Requested partner expertise*** | Able to run clinical trials, able to sponsor clinical trials. |

| **PROFILE** | |
|---|---|
| **UK** | **John A MILLS** |
| | john.mills@uhcw.nhs.uk |
| | Radiotherapy Physics Manager |
| ***Areas of activity*** | Radiotherapy, Hyperthermia |
| **ORGANISATION** | |
| ***Name*** | Department of Clinical Physics and Bioengineering, University Hospital Coventry and Warwick |
| ***Type*** | Other |
| ***Department*** | Radiotherapy Physics |
| ***Short description*** | A large General Hospital serving over a million people around the City of Coventry. Research and Academic links with local universities. The Department of Clinical Physics and Bioengineering provides services in radiation protection, nuclear medicine, imaging, biomedical equipment and radiotherapy. |
| **PROJECT** | |
| ***Research project*** | ***Decision Tools for radiotherapy treatment strategies*** |
| ***Description of project*** | Radiotherapy treatment is becoming technologically more sophisticated and therefore complex and expensive. Difficult chooices need to be made between the resource to be used for a treatment and the clinical benefit. In this project the intnention is to develop and test clinical decision tools which will be of benefit to clinicians making these choices. The project will build on work already completed within the MAESTRO project to develop methods of optimising the use of Adaptive Radiotherapy for clinical benefit. |
| ***Expertise offered*** | Control engineering expertise with a full range of techniques for process control and decision making. Extensive experience in Industrial, medical and other applications. Radiotherapy Physics expertise in dose prediction, treatment planning, dosimetry and some radiobiology |
| ***Requested partner expertise*** | Clinical radiotherapy treatment. Interest in decision tools in medicine, radio-biological modelling, treatment planning system development |

| **PROFILE** | |
|---|---|
| **France** | **Jean-Michel MOLINA** |
| | maladies.infectieuses@sls.aphp.fr |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | Head of Department |
| ***Areas of activity*** | HIV, AIDS, tuberculosis, immunocompromised, transplant recipients |
| **ORGANISATION** | |
| ***Name*** | Saint-Louis Hospital and University of paris 7 |
| ***Type*** | University |
| ***Department*** | Department of Infectious Diseases |
| ***Short description*** | Expertise in HIV/AIDS, tuberculosis and clinical research |
| **PROJECT** | |
| ***Research project*** | ***Clinical research in HIV AIDS*** |
| ***Description of project*** | Assess new drugs and new treatment stratégies for patients |
| ***Expertise offered*** | Work with ANRS national agency for AIDS research |
| ***Requested partner expertise*** | fluent in english, speak french, experience in HIV AIDS |

| | |
|---|---|
| **PROFILE** | |
| **Sweden** | **Mamoun Muhammed** |
| | mamoun@kth.se |
| | Head of the Department, Director Nano Characterisation Centre |
| ***Areas of activity*** | Nanotecfhnology, Drug delivery, Biodiagnostics |
| **ORGANISATION** | |
| ***Name*** | Royal Institute of Technology (KTH) |
| ***Type*** | University |
| ***Department*** | Functional Materials |
| ***Short description*** | Research and Education |
| **PROJECT** | |
| ***Research project*** | ***Nanomedicine: The use of Nanoparticles in biomedical applications.*** |
| ***Description of project*** | Development of multifunctional nanoparticles for drug delivery, diagnositics and imaging. |
| ***Expertise offered*** | Nanoparticles synthesis and processing, Characterisation of Nanoparticles, The use of nanoparticles in specific application; e.g. drug and gene delivery into the inner ear. |
| ***Requested partner expertise*** | Use of Nanoparticles in several medical applications |



This event is funded by the Seventh Framework Programme, European Commission

| PROFILE | |
|---|---|
| **Austria** | **Christa Noehammer** |
| | christa.noehammer@ait.ac.at |
| | Head of Molecular Medicine |
| ***Areas of activity*** | Biomarker, Microarrays, Cancer, Infectious Disease, Small Animal positron emission tomography |
| **ORGANISATION** | |
| ***Name*** | AIT Austrian Institute of Technology |
| ***Type*** | Research center |
| ***Department*** | Molecular Medicine |
| ***Short description*** | AIT – the Austrian Institute of Technology is Austria's largest non-profit, non-university research organization. AIT comprises five specialised departments ( Mobility, Energy, Health & Environment, Safety & Security, Foresight Policy & Development) working on the key infrastructure issues of the future thereby developing technological innovations, methods and solutions for industry and customers from public institutions. Embedded in the Health & Environment Department the research unit Molecular Medicine, has its primary focus in biomarker development for personalized medicine. Research activities of the Molecular Medicine group range from molecular imaging using animal positron emission tomography accompanied by computational tools for treatment planning in nuclear diagnostics and targeted radiotherapy to the development of molecular diagnostic assays for infectious disease and cancer. |
| **PROJECT** | |
| ***Expertise offered*** | Development of molecular assays for infectious disease and cancer diagnostics (gene expression and DNA methylation analysis using microarrays and high throughput real-time PCR)<br>Small animal positron emission tomography and PET Tracer Development |

| PROFILE | |
|---|---|
| **ITALY** | **Giuseppe Novelli** |
| | novelli@med.uniroma2.it |
| | Ordinary University Professor |
| **ORGANISATION** | |
| ***Name*** | Unit of Medical Genetics, Department of Biopathology, Tor Vergata University Biopathology and Diagnostic Imaging |
| ***Type*** | University |
| **PROJECT** | |
| ***Research project*** | **Genetic association of OLR1 gene polymorphism with cardiovascular disease and setting up of new protocols for inhibition of OLR1 expression by delivery system of antisense oligonucleotide** |
| ***Short description*** | Several studies have correlated cardiovascular disease (CVD) susceptibility with the genetic background of ethnic groups. In particular, it has observed that genetic variants |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | that contribute to risk of common disease may differ in frequency across populations more than random variants in the genome (Kirk E. Lohmueller et al., 2005). Since different populations are subject to distinct environments, natural selection may produce population-specific allele frequencies. The human OLR1 gene plays a central role in uptake of ox-LDL. OLR1 is the main receptor for ox-LDL and plays an important role in the pathogenesis of cardiovascular diseases, especially atherosclerosis. We have identified polymorphisms within the OLR1 gene which are associated with coronary atherosclerosis (CAD) and AMI in Italian population (Mango et al., 2003).<br>Moreover we genotyped the SNPs IVS4 -14 A>G (rs3736235, chr12: 10204342) and K167N (rs11053646, chr12: 10204715) on a sample of 1,229 individuals belonging to various African[Egypt, Libya (Tuareg), Benin (Bariba, Berba, Dendi, Fon)], Asian (Mongolia and Siberia),European (Italy, Spain, Bulgaria, Serbia, Turkey) and United States populations both of European and African ancestry. The results confirm significant genetic structuring among populations and suggest a possible basis for varying susceptibility to CVD among groups correlated with the geographical location of populations linked with the migrations out of Africa, or with different life-style.<br>The incidence of ischemic heart disease (IHD) has markedly increased in India over the past few years. Considering the variations in racial, dietary and lifestyle patterns in our population, we consider essential to study the biology of coronary atherosclerosis in this population.<br>The aim of the project is two fold:<br>1. To analyse Indian population to determine the association between OLR1 genotype and the cardiovascular disease.<br>2. To generate a new delivery system for LOX-1 inhibition. |
| ***Expertise offered*** | The Unit of Medical Genetic of Tor Vergata University has all expertise in genetics, molecular biology and gene therapy. This unit has over twenty years experience studying nucleic acid sequence and function. We have developed novel techniques and new approaches to understanding the molecular basis of genetic diseases |
| ***Requested partner expertise*** | Medical unit for patient recruitment and biological sample (peripheral blood, tissue) collection |

| **PROFILE** | |
|---|---|
| **ITALY** | **Giuseppe Novelli** |
| | novelli@med.uniroma2.it ; presidenza@med.uniroma2.it |
| | Dean of Faculty of Medicine |
| ***Areas of activity*** | genetic, virology, pathology, neurobiology, biochemistry, gastroenterology parassitology and immunotechnology |
| **ORGANISATION** | |
| ***Name*** | University of Rome, Tor Vergata |
| ***Type*** | University |
| ***Department*** | Faculty of Medicine and Surgery |
| **PROJECT** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Research project*** | ***Genetic , diagnosis and therapies of cardiovascular, inflammatory, neurodegenerative, parasitological and infective diseases.*** |
| ***Short description*** | Following are described relevant ongoing projects in our Institution.<br>Prof. Novelli's laboratory (novelli@med.uniroma2.it) is involved in research projects of molecular, human and medical genetics and, in particular, on genomics and multigenic analysis of psoriasis, congenital cardiopathies, cardiovascular diseases, miotonic distrofies and cystic fibrosis. New innovative gene therapy platforms have been set up and developed tests based on genetic and expression microarrays. Recently we have described the molecular basis of Mandibular-Acral-Displasy (MAD) and identified a new isoform of the ox-LDL receptor.<br>CHAIN (Collaborative HIV and Anti-HIV drug resistance network) is a large scale integrating project aimed to effectively and durably combat new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern Europe and in heavily affected resource-poor regions in Africa. This is achieved through our pan-European network of surveillance and basic research activities. The project studies novel resistance mechanisms and exploits laboratory monitoring tools, in order to improve the clinical management of resistance to anti-HIV (cf.perno@uniroma2.it).<br>The Immunotechnology laboratory of Prof. Biocca, (biocca@med.uniroma2.it) has extensive experience in all aspects of the recombinant antibody technology, including cloning of V-regions by using human phage display libraries and expression of intrabodies for phenotypic knockout experiments applied to neurodegenerative and cardiovascular diseases.<br>Aim of Prof. Coletta/Marini's group (stefano.marini@uniroma2.it) is to exploit expertise in modelling drug design, protein structure determination, enzyme characterization and kinetics, inhibition assay development and in vitro and in vivo pharmacodinamics to develop novel inhibitors of key enzymes in the Plasmodium and Schistosoma lifecycles. Our group is also involved in identification of new targets for diagnosis and therapy in the medical field (both human and veterinary) for relative applications on mammalians and farmyard animals, starting from proteins cloned from Mycobacterium tuberculosis.<br>Aim of Prof. Monteleone's group is to study the inflammatory bowel disease. Current treatment is based upon steroid therapy or neutralizating the effect of pro-inflammatory cytokines, especially TNF alpha. Despite their efficacy, many patients eventually requires surgery for refractory disease or complications. A particularly innovative aspect of our approach is the examination of both bacterial and host derived proteases and interaction between them. The ultimate aim is develop novel therapeutics and increased understanding of the disease (gi.monteleone@med.uniroma2.it).<br>Prof. Sinibaldi Salimei's group is involved in studies on the molecular mechanisms of different degenerative and inflammatory diseases in mammalians, in a therapeutic perspective (paola.sinibaldi@uniroma2.it). |
| ***Expertise offered*** | Basic and advanced research in genetics, immunology, immunotechnology, biotechnology, biochemistry and clinic. |

| **PROFILE** | |
|---|---|
| **HUNGARY** | **Ferenc Olasz** |
| | olasz@abc.hu |
| | Principal investigator, groupleader |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Areas of activity*** | mobile elements, bacteria, E. coli, pathogenic bacteria, genomics, pathogenicity island |
| **ORGANISATION** | |
| ***Name*** | Agricultural Biotechnology Center |
| ***Type*** | Research center |
| ***Department*** | Host-Pathogen Interaction group |
| ***Short description*** | The Agricultural Biotechnology Center (ABC) deals with biotechnology research and development for an environmentally sound Hungarian agriculture and participates in the training of biotechnologists and coordinating of biotechnology research activities. ABC is the largest institute among the research organizations sponsored by Ministry of Agriculture and Rural Development (MARD) with 126 employees, 60 of which belong to the scientific staff, including graduate students in various PhD programmes and visiting scientists from European and other countries.<br>The institute has state of art technical facilities, with an overall laboratory area of 4000 m2, a greenhouse (800 m2), and animal houses for small laboratory animals. The equipment and the basic instrumentation of the institute meet the international standards.<br>The research activity of ABC focuses on the molecular aspects of plant and animal development, breeding and modern environmental technologies, dominated by molecular and cellular approaches, to develope products and technologies for utilization.<br>The research groups of the institute study in their selected fields the molecular mechanisms involved in plant parasite interactions, abiotic and biotic stress resistance, work on breeding of tolerant and multi-resistant species and improving bioenergy plants. With the help of comparative genetic mapping and engineering and using molecular marker technology, developed gene-technology systems, bioinformatics they elaborate innovative techniques and transformation methods. Animal biology projects are aimed at creating transgenic animal models to analyze specific gene expressions and nuclear transfer techniques, studying the role of livestock genes in milk composition and production. The areas of research cover the most strategic cultivars (vital food plants: potato, cereals, legumes and vegetables like beans, maize and the 'Hungaricum' paprika) and the special nutritional and medical aspects of livestock and laboratory animals.<br>Our research teams are involved in several projects supported by MARD and national R&D funds and successfully participate in multilateral cooperations and the EU Framework Programmes. Partnered by leading scientific research and educational institutes, collaborative projects with international partners represent an important section of the research activity.<br>Based on the concept of the Foundation Letter of the institute, ABC encourages the implementation of scientific results and the utilization of its intellectual property benefits and has played initiative role in establishing knowledge-based spin-off companies in Hungary. Today there are three enterprises hosted by the institute which serve DNA sequencing and GMO analytics by the Biomi Ltd., provide immunodiagnostics of toxins and antibiotics in food and feed by the Soft Flow Biotechnology Ltd., and develops composite soil inoculation products by the Saniplant Ltd.<br>The Agricultural Biotechnology Center welcomes international and national meetings and workshops, regularly hosts training and educational programmes. Each year the institute organizes a small conference the "ABC Days" which provides a forum for the staff scientists to introduce their newest achievements and an occasion for the |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | colleagues and guests to present new opportunities. |
| **PROJECT** | |
| ***Research project*** | ***Host-pathogen interaction: Vaccination and synthetic biology – a bacterial genom puzzle*** |
| ***Description of project*** | Generally there are numerous pathogenicity/virulence factors of pathogenic bacteria (5-10 or even more) as the pathogenetic processes usually require harmonized functions of several genes and operons involved in the complex phenotype. Besides these "major" factors often many other genes, "minor factors", are required, which can further modify the pathogenic phenotype. These genes, so called "fitness genes", have importance only under specific circumstances (e.g. antibiotic resistance genes) and they have key role in the adaptation and propagation of the bacteria in the host. The fitness genes generally have no direct connections to the major factors, but it can occur that the major factors can not properly be expressed in a genetic background lacking these factors. Probably this complexity can explain the age-old experimental observation that in spite of the transfer of numerous genes or clusters of genes that have been identified to have central role in causing diseases into a similar non-pathogenic strain, the development of the original pathogenicity in the new host is not observed. In these cases the lack of unknown "minor" or "fitness factors" can prevent the appropriate expression or functioning of the known pathogenicity genes or cause low viability of the new strain in the habitat the original pathogen was adapted to. The missing factors probably reside in the large class of genes known from genome annotations as "hypothetical protein" or "gene with unknown function". Briefly, the pathogen phenotype may be the result of co-evolution of the major pathogenicity factors and the genetic background of the pathogenic organism. This may explain why the background factors are often barely determined by mutagenesis screens. Consequently, a more complete knowledge of these factors may highly promote the development of new, effective and safe vaccines against many diseases.<br>In the frame of a new project we wish to identify the pathogenicity factors of model enterotoxigenic E. coli (ETEC) strain causing heavy losses for the stock-raising by applying a new, synthetic approach. For this we apply the genetic background of a reduced-genome E. coli strain where the pieces of the mosaic of pathogenicity can be compiled resulting in a synthetic model organism. The genomic segments and plasmids of the pathogenic strain will be transferred into the well-defined genetic background of the minimal E. coli and the resulting recombinant strains will be characterised by phenotyping tests to search for the appearing pathogenicity factors. Narrowing the segments and applying recurrent phenotype tests will hopefully lead, step-by-step, to identification of numerous pathogenicity factors, genes, operons and islands. As a final result, the major factors of virulence that are most important will be assembled in a synthetic strain. This strain would considerably help in development of an effective, as yet lacking, vaccine in the future. Besides, the project will provide large amount of genomics data/results and a first whole bacterial genome sequence in Hungary. The generation of such synthetic strain itself would evoke a positive international response and contribute to the knowledge accumulated on the pathogenicity factors. This would also open new ways in identification of genes playing key role in pathogenicity and in applying these genes in development of new vaccination methods. We hope that our "reversed" approach will operate in exploration of such complex phenotypes like the |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | pathogenicity or virulence. |
| ***Expertise offered*** | Genetic manipulation of bacteria, biotechnological approach, |
| ***Requested partner expertise*** | expertise in biotechnology and microbiology, occurently sequencing facilities for sequencing genoms of bacteria, strain collections |

| **PROFILE** | |
|---|---|
| **Estonia** | **Kaia Palm** |
| | kaia@protobios.com |
| | CEO |
| **ORGANISATION** | |
| ***Name*** | ProtoBioS, Ltd |
| ***Type*** | SME |
| ***Department*** | R&D |
| ***Short description*** | Since the foundation of Protobios in 2003, the company has established a clear and consistent mission to cure the unseeable before it hurts.<br>Protobios develops novel drug candidnates and diagnostic systems for oncology, immune system and neurological disordes. In addition, the comapny also offers biomedical scientific and development services to industry. |
| **PROJECT** | |
| ***Research project*** | ***Integrative diagnostics for early cancer detection*** |
| ***Description of project*** | Numerous studies indicate that the altered autoimmunity as detected by the appearance of cancer-related antibodies preceeds cancer. Utilizing proprietary phage display technology, we have generated a library of immunogenic peptides representing autoantigens for detection of a variety of carcinomas from blood sera. These peptides could be used to develop blood-based early detection cancer tests. |
| ***Expertise offered*** | Protobios has a proprietary screening system for biomarker discovery for the development of blood-based diagnostic systems. The company uses genomic and proteomic techniques to identify subtle changes in the blood profile of nucleic acids and proteins that result from disease or treatment. At present we are optimizing the transfer of our proprietary biomarkers to multianalyte assay platform. |
| ***Requested partner expertise*** | The project will require clinical expertise from India to carry out clinical studies in India. There is also a need for bioinformatic expertise |

| **PROFILE** | |
|---|---|
| **Belgium** | **Juan Carlos Palomino** |
| | jcpalomino@itg.be |
| | Scientist |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| *Areas of activity* | tuberculosis, mycobacterial diseases |
| **ORGANISATION** | |
| *Name* | Prince Leopold Institute of Tropical Medicine |
| *Type* | Research center |
| *Department* | Microbiology - Mycobacteriology Unit |
| *Short description* | The Institute of Tropical Medicine in Antwerp, Belgium is an international recognized organization addressing several topics in infectious and tropical diseases with especial reference to those affecting people in less-developed countries. |
| **PROJECT** | |
| *Research project* | ***Rapid detection of tuberculosis drug resistance*** |
| *Description of project* | The project aims to develop rapid methods to detect resistant strains of Mycobacterium tuberculosis directly from clinical samples |
| *Expertise offered* | Microbiological techniques, molecualr detection |
| *Requested partner expertise* | Evaluation of new diagnostic methods |

| | |
|---|---|
| **PROFILE** | |
| **ESTONIA** | **Pradeep PANDA** |
| | pradeep@mia.org.in |
| | Senior Researcher<br>Implementing community-based health insurance and measuring impact |
| **ORGANISATION** | |
| *Name* | Micro Insurance Academy |
| *Type* | Research Center |
| *Short description* | The MIA is a premier intermediary between science and micro insurance practitioners,through research insights that suit the reality at the base of the pyramid in rural and poor settings, or through improved methods for implementation of micro health insurance units. |
| **PROJECT** | |
| *Research project* | ***Developing efficient and responsive community based micro health insurance in India*** |
| *Short description* | This five-year research project, funded by the EU (FP7), is a collaborative project of six partner organizations: MIA, Erasmus University Rotterdam, University of Cologne, BAIF Development Research Foundation, Nidan and Shramik Bharti. By combining the rollout of three community-based health insurance schemes and an unprecedented emphasis on scientifically rigorous evaluation of their impact on the lives of the target population in terms of equitable healthcare access and financial protection over several years, this project seeks to build a solid and comprehensive knowledge base for micro health insurance initiatives in India. |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Expertise offered*** | Qualitative research, quantitative research, spatial analysis, Randomized Controlled Trials |
| ***Requested partner expertise*** | Same as above |

| **PROFILE** | |
|---|---|
| **AUSTRIA** | **Georg PAUCEK** |
| | eorg.paucek@medicon.at |
| | Ing |
| ***Areas of activity*** | independent consultancy in the medical laboratory diagnostics sector for strategic planning and structuring of efficient proces flows, networking and coperation of healthcare facilities,<br>under use of innovative laboratory analysis with IT logistics. |
| **ORGANISATION** | |
| ***Name*** | MEDICON Medical Consulting e.U. |
| ***Type*** | Other |
| ***Department*** | Management consulting Expert advice in respect of organising, equipping and networking |
| **PROJECT** | |
| ***Expertise offered*** | With more then 35 years of professional experience and certified - CMC - management quality in the medical laboratory sector our consulting and project services will result in the beswt possible outcome |

| **PROFILE** | |
|---|---|
| **France** | **Ramesh PILLAI** |
| | pillai@embl.fr |
| | Group Leader |
| ***Areas of activity*** | germline, gene regulation, miRNAs, piRNAs, epigenetics, noncoding RNAs |
| **ORGANISATION** | |
| ***Name*** | European Molecular Biology Laboratory (EMBL) |
| ***Type*** | Research center |
| ***Department*** | Grenoble Outstation, ncRNA group |
| ***Short description*** | EMBL Grenoble has three principle activities. We collaborate with the ESRF and ILL in developing methods and instrumentation for structure determination by X-ray and neutron crystallography. In our biology labs we do research in molecular structural biology notably in the fields of protein-RNA complexes involved in RNA metabolism and translation; protein-DNA complexes involved in transcription; structure, assembly and host-cell interactions of viruses, and proteins involved in membrane fusion. And lastly, we develop instruments and technologies dedicated to automated expression and crystallisation of proteins. |



This event is funded by the Seventh Framework Programme, European Commission

| PROJECT | |
|---|---|
| *Research project* | ***Regulation of gene expression by non-coding RNAs*** |
| *Description of project* | The aim of our research is to understand the molecular mechanisms by which non-coding RNAs, specifically microRNAs (miRNAs) and germline piwi-interacting RNAs (piRNAs), regulate gene expression. MicroRNAs are an abundant class of small non-protein-coding RNAs that function as negative gene regulators at the post-transcriptional level. They are involved in a wide variety of biological processes and it is becoming clear that these tiny RNAs perform critical functions during development and cell differentiation. Recently, mis-expression of miRNAs has been implicated in human cancers, underscoring the relevance of these RNAs in human health. |
| *Expertise offered* | Analysis of miRNAs in the context of gene regulation, disease states, mechanistic studies of RNA-protein complexes, bioinformatic analysis of small RNA datasets |
| *Requested partner expertise* | Partners interested in examining the role of non-coding RNAs in their field of study. |

| PROFILE | |
|---|---|
| **India** | **Kashi Nath PRASAD** |
| | knprasad@sgpgi.ac.in |
| | Professor |
| *Areas of activity* | Microbiology, Antimicrobial Resistance, CNS infection, Neurocysticercosis, Helicobacter pylori |
| **ORGANISATION** | |
| *Name* | Sanjay Gandhi Postgraduate Institute of Medical Sciences |
| *Type* | University |
| *Department* | Microbiology |
| *Short description* | It is an Institute and 800 bedded tertiary care health centre with the status of a deemed university, funded by the State Government. There are 25 academic departments belonging to different disciplines of modern medicine. It offers MD, DM, MCh and PhD degrees, and admission is through all India competetive examination. The aims are quality teaching/training, patient care and research. |
| **PROJECT** | |
| *Research project* | ***Identification and Characterization of Emerging Antimicrobial resistance Bacteria in India*** |
| *Description of project* | Emerging antimicrobial resistance is a major threat to human health in 21st century. There are reports of emergence of novel family of drug resistance determinants in Salmonellae, rmtC that confers high level resistance to aminoglycosides, clinically very relevant antibiotics in India. Interestingly more than half of such patients had travel history in India. Till date no work has been done in India to assess the presence and spread of rmtC or other genes belonging to the same family such as armA, rmtA, rmtB |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | and rmtD. Hence, we propse to identify and characterize these emerging resistant genes in India. |
| ***Expertise offered*** | More than 3000 Enterobacteriaceae members are isolated each year with animoglycoside resistance rate 20-27%. The department has the facilities and expertise to detect resistance bacteria both by phenotypic and genotypic methods. Besides expertise, basic laboartory and equipment facilities such as thermo-cycler, real time PCR, automated blood and body fluid culture system, electrophoresis, transilluminator, spectrophotometer etc are available.The Indian investigator has more than 120 publications in peer reviewed National and International journals. |
| ***Requested partner expertise*** | Prof Bruno Gonzalez Zorn (UCM, Madrid, Spain) has a long experience in National and International projects related to antimicrobial resistance determinants, especially 16S rRNA methyl transferases. All laboartory infrastructures and technical know-how related to antimicrobial resistance following international standards are available. As such PCR, Southern blot, hybridizations, RT-PCR, cloning and sequencing, PFGE etc are routine in his laboaratory. |

| **PROFILE** | |
|---|---|
| **GERMANY** | **Horst PRZUNTEK** |
| | przuntekh@t-online.de |
| | Head of the Department |
| ***Areas of activity*** | Health reserch |
| **ORGANISATION** | |
| ***Name*** | Evangelisches Krankenhaus Hattingen |
| ***Type*** | University and Research Center |
| ***Department*** | Department of Neurology and Complementary Medicine |
| ***Short description*** | University associated hospital |
| **PROJECT** | |
| ***Research project*** | ***Neurodegenerativ disorders and health care*** |
| ***Short description*** | Neurology and complementarx medicine |
| ***Expertise offered*** | Clinical experience, basic research in genetics, clinical pharmacology and experimental neuropharmacology |
| ***Requested partner expertise*** | Basic modern biochemical and pharmacological Ayurveda research |

| **PROFILE** | |
|---|---|
| **Hungary** | **Jozsef RACZ** |
| | raczj@t-online.hu |
| | senior researcher |
| ***Areas of activity*** | drug abuse - recovery narratives from addictions - qualitative studies - drug policy - |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | injecting drug users' narratives |
| **ORGANISATION** | |
| ***Name*** | Institute for Psychology, Hungarian Academy of Sciences |
| ***Type*** | Research center |
| ***Department*** | Social Psychology Group |
| ***Short description*** | Social psychological studies using qualitative methods and narrative approach. The studies incorporates reserarches on national identities and on drug users' narratives. The common elements are the narrative approach and analytical technics. |
| **PROJECT** | |
| ***Research project*** | ***Qualitative studies on drug users narratives*** |
| ***Description of project*** | Analysing drug users' as well as drug policy narratives from a qualitative point of view: narrative approach, linguistic analysis. |
| ***Expertise offered*** | Expertise on qualitative field methods and qualitative - mostly narrative - analysis (Atlas.ti, NooJ), linguistic analysis (text linguistics); psychiatrical and social psychological knowledge to analyse texts. |
| ***Requested partner expertise*** | Qualitative methodology, interesting in substance use behaviors and controlling policies. Expertise in organizing consortiums. |

| | |
|---|---|
| **PROFILE** | |
| **HUNGARY** | **V. P. RAO** |
| | rao.vp@i-brain.co.uk |
| | Director |
| **ORGANISATION** | |
| ***Name*** | Renaissance Clinical and Translational Science Institute |
| ***Type*** | Research Center |
| ***Department*** | Science e Technologies |
| ***Short description*** | RENAISSANCE CTSI is a premier institute that concentrates on basic, translational, and clinical research. RCTSI also focuses on developing community clinicians, clinical practices, networks, professional societies, and industry to facilitate the development of new professional interactions as well as research. RCTSI endeavors to work toward increasing funds for pilot projects. We aim to enable diverse investigators and academic units, in partnership with communities and health systems, to effectively pursue research goals. Research studies at RENAISSANCE help translate knowledge from the cellular and molecular level to create interventions that would eventually treat and help individuals. We carry out exhaustive and extensive research to improve our knowledge on various diseases and to discover new ways to prevent, diagnose and treat diseases. Joint Venture Company with French and Bristish partcipation |
| **PROJECT** | |
| ***Research project*** | ***Working on Clinical research in the areas of Oncology, Immunology and Infectious Disease*** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | Research and Development and Translational science Development |
| ***Expertise offered*** | Co-partnering |
| ***Requested partner expertise*** | Technology transfer |

| **PROFILE** | |
|---|---|
| **UK** | **Caroline Relton** |
| | c.l.relton@ncl.ac.uk |
| | Senior Lecturer |
| ***Areas of activity*** | epigenetics, genetics, epidemiology |
| **ORGANISATION** | |
| ***Name*** | Newcsatle University |
| ***Type*** | University |
| ***Department*** | Human Nutrition Research Centre and Institute for Ageing and Health |
| ***Short description*** | Research intensive university engaged in a broad portfolio of clinical and basic medical research. |
| **PROJECT** | |
| ***Research project*** | ***The role of epigenetic variation in common complex disease*** |
| ***Description of project*** | My programme of research involved the measurement of inter-individual varition in DNA methylation and how this relates to disease risk and to non-pathological ageing |
| ***Expertise offered*** | epigenetics, epidemiology, genetics, nutrition |
| ***Requested partner expertise*** | partners interested in epigenetic studies |

| **PROFILE** | |
|---|---|
| **France** | **Vincent RIBRAG** |
| | ribrag@igr.fr |
| | M.D. |
| ***Areas of activity*** | haematology |
| **ORGANISATION** | |
| ***Name*** | Insitut Gustave Roussy |
| ***Type*** | Other |
| ***Department*** | Medicine |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | anticancer center Non Profit |
| **PROJECT** | |
| ***Research project*** | ***lymphomas pharmacology including animal medels (especially mantle cell lymphoma)*** |

| | |
|---|---|
| **PROFILE** | |
| **UK** | **Polly ROY** |
| | Professor of Virology |
| ***Areas of activity*** | Diseases caused by Orbiviruses (African horse sickness, bluetongue and epizootic haemorrhagic disease): development of new generation vaccines and accompanying tests) |
| **ORGANISATION** | |
| ***Name*** | London School of Hygiene and Tropical Medicine |
| ***Type*** | University |
| ***Department*** | Infectious and Tropical Diseases |
| ***Short description*** | London School of Hygiene and Tropical Medicine is a well equipped research centre focusing on the study of tropical diseases. It is dedicated to the improvement of health worldwide through the pursuit of excellence in research and advanced training in national and international public health and tropical medicine, and through informing policy and practice in these areas. The research centres at LSHTM include researchers into pathogens (including viruses, bacteria and parasites) as well as immunologists and a strong epidemiology team, who have strong ties with developing countries, and who monitor, produce and provide vaccines for important infectious diseases. Many members of the research centres at LSHTM are involved with various committees of WHO, Global Alliance for Vaccines and Immunization (GAVI) and other vaccine development initiatives, including the Gates Foundation and European commission. |
| **PROJECT** | |
| ***Research project*** | ***Development of multivalent vaccines for BTV, EHDV and AHS (ORBIVAC)*** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | The vector-borne Bluetongue (BT) disease of ruminants, which is endemic in most tropical and subtropical countries (including India), has recently become widespread throughout European countries, having expanded from Northern and Western into Southern and Eastern Europe. This has resulted in the deaths of millions of animals and has caused massive economic losses to the agricultural economies of Europe. Two other genetically closely BTV related viruses, African Horse Sickness virus (AHSV) and Epizootic Hemorrhagic disease virus (EHDV), are also transmitted by same insect vectors, and all three viruses present current and potential future challenges to European agriculture. The overall aims of this FP7 project (in which Roy is the coordinator), are to develop novel, designer, multivalent vaccines for BTV, AHSV and EHDV as each has multiple serotypes; to understand the best vaccination strategy to elicit multi-serotype protection; and to develop new reagents and methods for rapid diagnosis and typing of orbivirus outbreaks and to distinguish infected and vaccinated animals. The project aims to use a coordinated multipartner approach and builds on specific expertise in Europe as well as also links out to other International efforts in USA and S. Africa. In addition to the immediate objectives of this project, the long term goal would be to promote cooperation between the Indian and European scientific communities. |
| ***Expertise offered*** | Professor Polly Roy is a Professor of Molecular Virology in the Department of Infectious and Tropical and Diseases. Professor Roy's group is one of the leading laboratories in the world in orbiviruses, particularly Bluetongue virus, and through a combination of virology, molecular and structural studies, she has been instrumental in paving the way to the complete understanding of orbiviruses as well as improved diagnostics and vaccines. Her contribution to virology, in particular to virus structure and assembly, has been recognized by her peers worldwide. Roy was first to demonstrate that simultaneous expression of several recombinant viral proteins leads to the assembly of virus-like particles (VLPs). This fundamental observation led to the development of technology to be applied to other viruses and VLP generation, such as SARS, HIV, Influenza, Rotavirus and Norwalk virus. Recently Roy pioneered the first reverse genetics system for orbiviruses (the synthesis of infectious virus solely from synthetic genes), a major achievement that will facilitate to generate designer live vaccines. Over the last 20 years, Professor Roy supervises routinely a large group of postdoctoral scientists (12-15) and doctoral students including researchers from India and other developing countries. In addition to her extensive research background (total publications, 285), Professor Roy has a wide range of experience in teaching and research in developing countries. She has been involved in 12 EU funded research networks, 9 of which she has been the coordinator. |
| ***Requested partner expertise*** | The project will require expertise from India in order to develop vaccines for Indian strains and to disseminate the vaccines and diagnostic reagents in collaboration. |

| **PROFILE** | |
|---|---|
| **Lithuania** | **Kestutis Sasnauskas** |
| | sasnausk@ibt.lt |
| | Chief scientist |
| ***Areas of activity*** | Yeast expression; recombinant nucleocapsid protein, virus-like particles; Saccharomyces cerevisiae; Pichia pastoris |



This event is funded by the Seventh Framework Programme, European Commission

| ORGANISATION | |
|---|---|
| ***Name*** | Institute of Biotechnology |
| ***Type*** | Research center |
| ***Short description*** | The Institute of Biotechnology (IBT) is non-profit state research institute, the leader in molecular biotechnology and biomedical research in Lithuania. IBT is internationally acclaimed for its multidisciplinary research on the structure of DNA restriction-modification enzymes, yeast genetics, development of biomedical recombinant proteins, small molecule inhibitors, and bioinformatics. The highest level of research performed at IBT in all these areas is proven by successful participation in EU FP (FP5, FP6, FP), including the award of the Centre of Excellence in 2002 and other competitive international programs (HHMI, NIH, EEA), scientific publications in peer reviewed journals, and the highest citation figures among the Lithuanian research institutions. High level scientific research at the institute is in step with applied, and thus succeeded in generation of four research-based biotech spin-off companies in Lithuania efficiently acting on the international market (Fermentas UAB, Sicor Biotech UAB). |
| **PROJECT** | |
| ***Research project*** | ***Preparation of recombinant viral proteins for diagnostics and vaccine development*** |
| Description of project | Viral surface, nucleocapsid or other viral proteins are expressed in yeast host such as S.cerevisae , P.pastoris , K.lactis. Purification of such proteins showed succesful results for different viruses: measles, mumps, RSV, PIV, human JCPyV and MCPyV, hamster HaPyV, RABV1, EBLV1, hantaviruses and many others. Chimeric virus-like particles (VLPs) obtained on the basis of HaPyV-VP1 with inserted peptide of interest are able to induce strong immune response specific to the inserted sequence. Application of purified recombinant viral proteins could be directed to diagnostics, vaccine preparation or scientific research purposes. |
| Expertise offered | Preparation and analysis of different recombinant viral proteins from Paramyxoviridea, Polyomaviridea, Lyssaviruses, Influenza, Bunyaviridea and other viral families and/or virus-like particles (VLPs) with application of know how in yeast expression and viral protein purification. |
| ***Requested partner expertise*** | Application of recombinant viral proteins or VLP for diagnostic kits, vaccine development, scientific research and etc. |

| PROFILE | |
|---|---|
| **Slovakia** | **Katarina Sebekova** |
| | katarina.sebekova@szu.sk |
| | Vicerector for Research Affairs |
| ***Areas of activity*** | polutants (endocrine disruptors), electric and magnetic fields, communicable diseases, chronic degenerative diseases,obesity, osteoporosis, nutrition, xenobiotics, |
| **ORGANISATION** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Name*** | Slovak Medical University |
| ***Type*** | University |
| ***Department*** | Department of Microbiology<br>Department of Experimental and Applied Genetics<br>Department of Virology<br>Department of Toxicology<br>Department of Radiation Hygiene<br>Department of Immunology and Immunotoxicology<br>Department of Environmental Medicine<br>Department of Clinical and Experimental Pharmacotherapy<br>Department of Bioactive Compounds and Nutrition Screening<br>Department of Toxic Organic Pollutants<br>Department of Prion Diseases |
| ***Short description*** | Research at SMU is focused on: environmental health and well being (polutants (endocrine disruptors), electric and magnetic fields, communicable diseases, chronic degenerative diseases, nutrition, xenobiotics, |
| **PROJECT** | |
| ***Expertise offered*** | expertise in: polutants (endocrine disruptors), electric and magnetic fields, communicable diseases, chronic degenerative diseases, nutrition, xenobiotics, |

| | |
|---|---|
| **PROFILE** | |
| **SWEDEN** | **Hari Shanker SHARMA** |
| | Sharma@surgsci.uu.se |
| ***Areas of activity*** | Blood brain barrier, brain edema, neuroprotection, brain pathology, nanodrug delivery, nanoparticles, neurotoxicity, substance abuse |
| **ORGANISATION** | |
| ***Name*** | Uppsala University |
| ***Type*** | University |
| ***Department*** | SurgicalSciences |
| ***Short description*** | Iestablishedan International Uppsala CNS InjuryResearch Group with participation from several EU, India and Australianscientists. This group also includes NIH scieintists from USA, US FDA, US Air Force and European Office of Aerospace Research & Development (EOAED).<br>Our group is committed to find neuro protective agent stotreat various CNS diseases. Currently weal so focussed on the useof nanoparticles in drugdelivery and tostudytheirtoxicity in the nervous system. |
| **PROJECT** | |
| ***Research project*** | ***Neuroprotection and Neurorepair strategies in CNS injury*** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | Brain or spinal cord injury caused by trauma, nanoparticles or substance abuse (e.g., morphine, methamphetamine, cocaine and MDMA) can lead to early neurodegenerative changes in the CNS. Our aim is to find neuroprotective agents that could be receptor modulators of neurotransmitters, or antibodies directed against neurotoxic agents. In addition, our aim is to see whether nano-drug delivery to these pharmacological agents may have an added value over the normal coimpunds. |
| ***Expertise offered*** | We could offer world class morphological techniques, light and electron microscopy, immunohistochemistry, animal models, electrophysiology and nanotechnology for drug delivery. |
| ***Requested partner expertise*** | Partners may have good laboratory facilities for animal experiments and have some interest in CNS disorders and their therapy. |

| **PROFILE** | |
|---|---|
| **INDIA** | **Prati Pal SINGH** |
| | drppsingh2005@gmail.com |
| | Professor |
| ***Areas of activity*** | Chemotherapy, immunology and neuroimmunomodulation of malaria, tuberculosis and leishmaniasis |
| **ORGANISATION** | |
| ***Name*** | National Institute of Pharmaceutical Education and Research |
| ***Type*** | Research Center |
| ***Department*** | Pharmacology and Toxicology |
| ***Short description*** | An Institute of National Importnace estblished through an act of Parliament devoted to higher education and research in pharmaceutical sciences; Thrust Areas of research are: malaria, tuberculosis and leishmaniasis. |
| **PROJECT** | |
| ***Research project*** | ***New models for cerebral malaria*** |
| ***Short description*** | Development of a new rodent model for the study of pathogenesis and chemotherapy of cerebral malaria |
| ***Expertise offered*** | Vast experience in parasitology, immunology and molecular biology of malaria, and necessary infrastructure |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Requested partner expertise*** | Knock-out mice, imaging facilities and microbiology/molecular biology infrastructure |

| **PROFILE** | |
|---|---|
| **India** | **Sarman Singh** |
| | sarman_singh@yahoo.com |
| | Head, Clinical Microbiology Division |
| ***Areas of activity*** | HIV-TB coinfection, HIV-other viral Coinfections |
| **ORGANISATION** | |
| ***Name*** | All India Institute of Medical Sciences |
| ***Department*** | laboratory Medicine |
| ***Short description*** | The All India Institute of Medical Sciences, was establsihed by an act of federal parliament of India in 1956 with main objective to cater highest level of medical care, research and teaching to Indian nationals at par with western countries. It is bigegst medical instition of India and more than 10,000 patient attend various OPDs and other clinic of its hospital. The institute awards graduate and postgraduate level degrees in 25 disciplines. |
| **PROJECT** | |
| ***Research project*** | ***To understand co-pathogenesis of TB and other viral infections in HV progression*** |
| ***Short description*** | Co-infections in HIV positive patients are major causes of death of AIDS patients. There are several factors involved in it. HIV enhances pathogenesis of these co-pathogens eg. TB , Hepatitis and herpes viruses, and also these co-pathogens trigger worsening of HIV pathogenesis. We are interested in studying various biomarkers and phathological pathways to understand this co-pathogenesis. |
| ***Expertise offered*** | Prof. Sarman Singh is well known clinical microbiologist and molecular biologist with significant contribtion in this field. |
| ***Requested partner expertise*** | Molecular biology and various signal pathways of pathogenesis |

| **PROFILE** | |
|---|---|
| **Germany** | **Till Roenneberg** |
| | sekretariat.imp@med.uni-muenchen.de |
| | Acting Head of the Institute for Medical Psychology<br>Head of the Centre for Chronobiology |
| ***Areas of activity*** | chronobiology, biological rhythms, epidemiology, shiftwork research |
| **ORGANISATION** | |
| ***Name*** | Ludwig-Maximilians-University - Institute for Medical Psychology -Centre for Chronobiology |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Type*** | University |
| ***Department*** | Medical Faculty |
| ***Short description*** | The IMP - Institute of Medical Psychology - has been founded in 1977 as an institution of the Medical Faculty of the University of Munich. During the last 30 years it has been cultivating interdisciplinary research.<br>We started off studying the visual system using psychophysical, neuropsychological, neurophysiological and neuroanatomical techniques.<br>Vision has kept its fascination for us, but new fields of research opened up like chronobiology, olfaction, sensorimotor control, temporal perception, learning, cognitive informatics, restitution of function after brain injury, as well as health and age related quality of life.<br>If there is one common denominator for our research that binds together past and present, it is "representation": how is the world around us mapped onto our brain and into visual perception; how are temporal experiences or the timing in biological systems embedded within the continuity of time; what are the mechanisms or representation in olfaction; how is subjective experience of health or disease mapped onto verbal representations; what are mathematical expressions of representations? |
| **PROJECT** | |
| ***Research project*** | ***Entrainment of the circadian clock.*** |
| ***Description of project*** | understanding entrainment from formalisms, lab experiments to real-life situations |
| ***Expertise offered*** | circadian biology and epidemiology |
| ***Requested partner expertise*** | circadian biology and epidemiology |

| | |
|---|---|
| **PROFILE** | |
| **Slovenia** | **Jožica Šelb - Šemerl** |
| | Jozica.selb@IVZ-RS.SI |
| | Senior health researcher |
| ***Areas of activity*** | Mortality statistics, automated coding, heat waves, sudden cardiac death |
| **ORGANISATION** | |
| ***Name*** | Institute of Punlic Haealth of the Republic Slovenia |
| ***Type*** | Research center |
| ***Department*** | Centre for Public Health Research |
| ***Short description*** | Institute of Public Health of the Republic Slovenia ( the Institute) is leading body in public health in Slovenia and is organised in five centres and Department for Health Statistics. The centres are daling with health assessment of Slovene population and it"s specific population groups, on prevention of infectious diseases, health care research, ecology, and health promotion. The Institute provids data and analyses on above mentioned fields for the Ministry of Health, running researches on actual or suddenly appeared health problems and work as a leading body in health promotion in Slovenia. |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | Its staf is also working as a partner with other subjects dealing with health problems in our country, and as a member of different EU organizations working on health( EUROSTAT, DG SANCO…..) |
| **PROJECT** | |
| Research project | ***Triggering factors for out of hospital sudden cardiac death*** |
| Description of project | Introduction:<br>Sudden cardiac death is one of the most serious problems of modern emergency medicine with serious social and economic consequences on victims family and the society. Is a multicausal event, every organic or functional heart disease can bring to it, and there are no specific anatomical changes which would point to a person at risk.<br>The hypothese is:<br>that short time acting potential triggering risk factors ( coffee, alcohol, physical activity…..) can trigger sudden cardiac death during or a short time after accused tasks were acting. Relative risk for sudden cardiac death is higher by simultaneous acting of long lasting risk factors which are at the same time also risk factors for ischemic heart disease.<br>Methods:<br>Sources of information are death certificates and the answers on the questionnaires sent to the closed family members and personal doctor of deceased. Data about health status and life style are collected with the focus on the last twenty four hours of life. Case crossover study design is used to establish a transitional effect of potential risk factors for triggering sudden cardiac death. Discriminate analyse tests which are the modulating risk factors that discriminate the best between the group of sudden cardiac death victims who died during the potential triggers are operating, and a group of deceased who died when potential triggers are not present. |
| Expertise offered | Design and monitor of epidemiologic study, offer questionnaires, cooperation with statistician in analysing results, assessing the results. To describe the quantitative differences in risk factors sudden cardiac death between women and men. |
| Requested partner expertise | Cooperation in all steps of above mentioned tasks, specialy computering case crossover statistic analyse. |

| | |
|---|---|
| **PROFILE** | |
| **INDIA** | **Pradeep Seth** |
| | seth.res.fdn@gmail.com,<br>consultant@pradeepseth.com |
| | President |
| ***Areas of activity*** | Virology, HIV, Tuberculosis, Vaccinology, Microbiology |
| **ORGANISATION** | |
| ***Name*** | SETH RESEARCH FOUNDATION |
| ***Type*** | Other |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Short description*** | Seth Research Foundation is a non profit organization registered with the Government of Delhi.The mission of this organization is to conduct research to ensure a proper management of diseases, including infectious, non-infectious, malignancies and genetic disorders through next-generation diagnostic tests, discovery of newer drugs and treatment schedules and development of novel vaccines through Genetic engineering and Recombinant DNA technology. In addition, the Research Foundation will engage in developing research expertise among young scientists through short and long term training programmes. It will collaborate with other academic institutions of repute in India and abroad to achieve this objective. The Research Foundation will participate in promoting literacy, cultural and other social activities by Awareness programmes, Adult Education Classes, Lectures, Essay Competitions, Exhibitions, Symposia, Cultural Programmes, Press Conferences and seminars.The Research Foundation will undertake such other things/acts/activities, which are, necessary and which may be incidental or conducive to the attainment of any of the object of the society. |
| **PROJECT** | |
| ***Research project*** | ***MTB pathogenesis in HIV infected individuals by identification of microbial virulence and host factors*** |
| ***Description of project*** | HIV-MTB co-infection and interaction of these pathogens is complex and poorly understood. Though in India tuberculosis in HIV negative adults is mostly reactivation type, it is quite intriguing that reinfection is the most common mode of tuberculosis among HIV infected individuals.Therefore in this project we intend to study the pathogenesis of Mycobacterium tuberculosis in different stages of HIV disease particularly their interaction at molecuar level. This may help us to predict MTB progression in these patients and contribute to the identification of new potential therapeutic targets. |
| ***Expertise offered*** | Molecular typing of Mycobacterium tuberculosis strains<br><br>i) Vijaya Bhanu N, van Soolingen D, van Embden, Dar L, Pandey RM, Seth P. Predominance of a novel Mycobacterium tuberculosis genotype in Delhi region of India. Tuberculosis. 82, 2002, 105<br>ii) Vijaya Bhanu N, van Embden JD, van Soolingen D, Seth P. Two Mycobacterium fortuitum strains isolated from pulmonary tuberculosis patients in Delhi harbour IS6110 homologue. Diagnostic Microbiol Infect Dis. 48, 2004, 107-110.<br>iii) Vijaya Bhanu N, Banavalikar JN, Kapoor SK, Seth P. Suspected small-scale interpersonal transmission of Mycobacterium tuberculosis in wards of an urban hospital in Delhi, India. Amer J Trop Med Hyg. 70, 2004, 527-531.<br>iv) Singh UB, Suresh N, Bhanu NV, Arora J, Pant H, Sinha S, Aggarwal RC, Singh S, Pande JN, Sola C, Rastogi N, Seth P. Predominant Tuberculosis Spoligotypes, Delhi, India. Emerg Infect Dis. 10, 2004, 1138-1142.<br>v) Suresh N, Singh UB, Arora J, Pant H, Seth P, Sola C, Rastogi N, Samantaray JC, Pande JN. rpoB Gene Sequencing and Spoligotyping of Multidrug-Resistant Mycobacterium tuberculosis Isolates from India. Infect Genet Evol. 6, 2006, 474-483.<br><br>Molecular typing of Mycobacterium tuberculosis strains<br><br>i) Vijaya Bhanu N, van Soolingen D, van Embden, Dar L, Pandey RM, Seth P. |



This event is funded by the Seventh Framework Programme, European Commission

Predominance of a novel Mycobacterium tuberculosis genotype in Delhi region of India. Tuberculosis. 82, 2002, 105

ii) Vijaya Bhanu N, van Embden JD, van Soolingen D, Seth P. Two Mycobacterium fortuitum strains isolated from pulmonary tuberculosis patients in Delhi harbour IS6110 homologue. Diagnostic Microbiol Infect Dis. 48, 2004, 107-110.

iii) Vijaya Bhanu N, Banavalikar JN, Kapoor SK, Seth P. Suspected small-scale interpersonal transmission of Mycobacterium tuberculosis in wards of an urban hospital in Delhi, India. Amer J Trop Med Hyg. 70, 2004, 527-531.

iv) Singh UB, Suresh N, Bhanu NV, Arora J, Pant H, Sinha S, Aggarwal RC, Singh S, Pande JN, Sola C, Rastogi N, Seth P. Predominant Tuberculosis Spoligotypes, Delhi, India. Emerg Infect Dis. 10, 2004, 1138-1142.

v) Suresh N, Singh UB, Arora J, Pant H, Seth P, Sola C, Rastogi N, Samantaray JC, Pande JN. rpoB Gene Sequencing and Spoligotyping of Multidrug-Resistant Mycobacterium tuberculosis Isolates from India. Infect Genet Evol. 6, 2006, 474-483.

HIV and Tuberculosis Co-infection

i) Vajpayee M, Kanswal S, Seth P, Wig N, Pandey RM. Tuberculosis Infection in HIV infected Indian patients. AIDS Patient Care STDs. 18, 2004, 209-213.

ii) Sharma SK, Aggarwal G, Seth P, Saha PK. Increeasing HIV seropositivity among adult tuberculosis patients in Delhi. Indian J Med Res. 117, 2003, 239-42.

iii) Vajpayee M, Kanswal S, Seth P, Wig N. Spectrum of opportunistic infections and profile of CD4(+) counts among AIDS patients in North India. Infection 31, 2003, 336-40.

Molecular Diagnosis of Tuberculosis

i) Shankar P, Manjunath N, Lakshmi R, Aditi B, Seth P and Shriniwas: Identification of Mycobacterium tuberculosis by polymerase chain reaction . Lancet 335: 1990, 423.

ii) Seth P, Ahuja G K, Vijaya Bhanu N, Behari M, Bhowmik S, Broor S, Dar L & Chakraborty M : Evaluation of polymerase chain reaction for rapid diagnosis of tuberculous meningitis. Tubercle and Lung Dis, 77, 1996, 353-357.

iii) Dar L, Sharma S K, Bhanu NV, Broor S, Chakraborty M, Pande J N and Seth P: Diagnosis of pulmonary tuberculosis by polymerase chain reaction for MPB64 gene: An evaluation in a blind study. Indian J Chest Dis Allied Sci, 40, 1998, 5-16.

iv) Hemal AK, Gupta NP, Rajeev TP, Kumar R, Dar L, Seth P: Polymearse chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy and urine acid fast bacilli culture. Urology, 56, 2000, 570-574.

v) Singh, U B, Seth P. PCR Diagnosis of tuberculosis- Experience in India. Indian J Tuberculosis. 69, 2002, S20-S24.

vi) Bhanu NV, Singh UB, Chakraborty M, Suresh N, Arora J, Rana T, Takkar D, Seth P. Improved diagnostic value of PCR in the diagnosis of female genital tuberculosis leading to infertility. J Med Micrbiol. 54, 2005, 927-931.

vii) Suresh N, Singh UB, Arora J, Pande JN, Seth P, Samantaray JC. Rapid Detection of Rifampicin-resistant Mycobacterium tuberculosis by in-house, Reverse Line Blot Assay. 2006. Diagn Microbiol. Infect. Dis, 56, 2006, 133-140.

viii) Singh UB, Bhanu NV, Suresh VN, Arora J, Rana T, Seth P. Utility of polymerase chain reaction in diagnosis of tuberculosis from samples of bone marrow aspirate. Am J Trop Med Hyg.75, 2006, 960-963.

Genomic Diversity of HIVS-1 strains circulating in various parts of India.



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | i) Maitra A, Singh B, Banu S, Deshpande A, Robbins K, Kalish ML, Broor S & Seth P: Subtypes of HIV-1 circulating in India : Partial envelope sequences. AIDS Res Hum Retroviruses, 15, 1999, 941-944.<br>ii) Voevodin A, Crandall K A, Seth P & Mufti S A : HIV type 1 subtypes B and C from new regions of India and Indian and Ethopian expatriates in Kuwait. AIDS Res & Hum Retroviruses, 12, 1996, 641-643.<br>iii)Sahni AK, Prasad VVSP& Seth P. Genomic diversity of human immunodeficiency virus type 1 in India. . Int J STD AIDS, 13, 2002: 115-118.<br>iv)Gupta RM, Prasad VVSP, Rai A and Seth P. Analysis of HIV-1 subtype C full-length gag gene sequences from India: Novel observations and plausible implications. AIDS Res Hum Retroviruses 21, 2005, 1068-1072.<br>v) Gupta RM, Seth P, Prasad VVSP, Sahni AK, Jena J. Detection of Human Immunodeficiency Virus Type 1 (HIV-1) A/AE circulating recombinant form (CRF) in India: Possible implications. Med J Armed Forces India, 62, 2006, 316-320.<br>vi) Khan I F, Vajpayee M, Prasad VVSP, Seth P. Genetic Diversity of HIV-1 Subtype C env gene sequences in India. AIDS Res Hum Retrovirus 23, 2007, 934-940<br><br>HIV–Immunology<br>i) Vajpayee M, Kanswal S, Seth P, Wig N. Spectrum of opportunistic infections and profile of CD4(+) counts among AIDS patients in North India. Infection 31, 2003, 336-40.<br>ii) Vajpayee M, Kanswal S, Wig N, Seth P. Evaluation of CD4 counts and percentages in the HIV infected Indian population. Southeast Asian J Trop Med Public Health, 35, 2004, 144-146.<br>iii)Amatya R, Vajpayee M, Kaushik S, Kanswal S, Pandey RM, Seth P. Lymphocyte immunophenotype reference ranges in healthy Indian adults: implications for management of HIV/AIDS in India. Clinical Immunology, 112, 2004, 290-295.<br>iv)Vajpayee M, Kaushik S, Sreeniwas V, Wig N, Seth P. CDC staging based on absolute CD4 counts and CD4 percentag in an HIV-1 infected Indian population: treatment implications. Clin Exp Immunol 141, 2005, 485-490.<br>v) Kaushik S, Vajpayee M, Wig N, Seth P. Characterization of HIV-1 gag-specific T cell responses in chronically infected Indian population. Clin Exp Immunol. 142, 2005, 388-397.<br>vi) Kaushik S, Vajpayee M, Sreenivas V, Seth P. Correlation of T lymphocyte subpopulation with immunological markers in HIV-1 infected Indian patients. Clin Immunol. 119 (3), 2006, 330-338.<br>vii) Lotz M and Seth P : TGFB and HIV infection . Annals of New York Academy of Sciences 685, 1993. |
| ***Requested partner expertise*** | A scientist working in the field of molecular biology of Mycobacteria. |

| **PROFILE** | |
|---|---|
| **SWEDEN** | **Ram Singh** |
| | icn2005@sancharnet.in |
| | director |
| ***Areas of activity*** | Patient Care, health promotion and Disease prevention by functional foods and designer foods |



This event is funded by the Seventh Framework Programme, European Commission

| ORGANISATION | |
|---|---|
| *Name* | Halberg Hospital and Research Institute |
| *Type* | Hospital |
| *Department* | Medicine and Cardiology |
| *Short description* | Its small 25 bed hospital including 4 bed intensive care unit, xray, ultrasonography, laboratory for routine blood tests and assay of antioxidant vitamins and minerals. We treat primary to tertiary care patients and educate people in prevention of diseases. And conduct research. |
| **PROJECT** | |
| *Research project* | ***Effects of Functional Foods and Designer Foods and Ingredients on Clinical, Biochemical and bio- markers in metabolic Syndrome, a randomized, double blind, placebo controlled trial*** |
| *Short description* | **Background:** The increased prevalence of metabolic syndrome(MS) appears to be due to greater consumption of refined starches and sugar, w-6 fatty acids, trans fats and saturated fats and **low intake of functional foods,** rich in fibre, w-3 fat ,antioxidants and phytochemicals and sedentary lifestyle.However, no randomized clinical trial has examined whether incorporating designer functional foods, developed by farm to fork approach, into a hypocaloric dietary pattern, increases weight loss with beneficial effects on cardiovascular disease(CVD) risk factors and new biomarkers of MS.<br>**Objective:** The aim of this study would be to determine the effects of designer foods rich in w-3 fatty acids, in conjunction with prudent dietary pattern, on blood concentration of w-6/w-3 ratio and clinical and biochemical markers of MS and other coronary risk factors, as a mark of development of functional designer foods, under EU-India S$T Agreement.<br>**Subjects and Methods:** Obese adults, aged 50-65 years (50 men,50 women) with MS would be randomly assigned to receive dietary advise, either to receive w-3 rich designer foods dietary pattern(n=50) or typical fast food ,NCEP-step 1diet(n=50). All participants would be given the same dietary advice, in other respects for weight loss during a total follow up period of 28 weeks. Designer,s foods would be supplied by the BNL Foods group of companies(Belgium). Biochemical markers would be studied, at College of Engineering and Technology by scientists, blind to groups.<br>**Results:** Body weight, waist circumference and percentage body fat, particularly in the abdominal region, may decrease significantly in the designer food group compared to control group receiving fast food diet. The ratio of w-6/w-3 fatty acids in the dietary pattern and in the blood may be < 5, possibly 1:1 in the intervention group compared to control group. Markers of inflammation; IL-6,IL-2,IL-18,TNF-alpha, C-reactive protein may show significant reduction in the designer food group than control group.Blood glucose, plasma insulin, catecholamines, serotonin,cortosol, leptin, angiotensin converting enzyme, triglycerides, total cholesterol(TC), LDL-C and small dense LDL, apo B etc would show a significant reduction and HDL, apo –A, adiponectin, ghrelin would show a significant increase in the intervention group without such changes in the control group. Parameters of oxidative stress; malondialdehyde(MDA),TBARS,Diene conjugates, and superoxide dismutase would show significant reduction with increase in antioxidants; flavonoids, vitamins, E and C in the intervention group than in the control group.Genetic markers such as activating protein-1, early growth response protein-1, nuclear factor k B, fetuin-A protein may show significant reduction in the intervention group without such changes in the control group. |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | Imaging study of atheroma plaque in the carotids and intima-media thichness indicating endothelial function would show marked reduction in intervention group without such effects in the control group.MRI spectroscopy and positron emission tomography if available may show beneficial effects in the endothelial cells and cardiomycytes in the intervention group with out such benefits in the control group. Blood pressure variability may show significant reduction in vascular variability disorders in the intervention group compared to control group.<br>**Conclusions:** Designer functional foods dietary pattern may be effective means of providing healthy ratio of w-6/w-3 fatty acids in the blood resulting in to marked reduction in inflammation and cardiovascular risk factors and other biomarkers of MS. This finding may result in to development of designer, functional foods in India by the EU Industry with Indian partnership |
| ***Expertise offered*** | **Dr RB Singh ,MD,** Former Professor of Medicine, Subharti Medical College, Meerut,Presently<br>- Hon fellow, Halberg Chronobiology Center, Univer. Of Minn Medical School, Mineapolis,USA<br>- Member and fellow of more than 15 national and international societies.<br>- Contributed >350 research papers in peer reviewed journals and books.<br>- Editor, World Heart Journal( Novascience,USA), The Open Nutra Jour(Bentham Science,USA).<br>1. Receive 12, national and international awards;<br>2.Contributed 6 books on nutrition in health and Disease, including monographs on Hypertension and Coronary Artery Disease;<br>3.International expert on Preventive Cardiology; **drug trials,Nutrients, foods, diet and Nutraceuticals;** magnesium,heart disease in women,Brain-heart interactions,HRV,BPV;<br>4.Discovered new antioxidant formulations for reversal of heart failure,renal failure and prevention of remodeling.: 3 patents in the Indian patent office,one heart failure given;<br>5.Founder President ,International College of Cardiology,2nd Congress in Slovakia,April 23-27,2002,3rd Congress in Taiwan,Nov.2004,4th ICCD,Mumbai,2005, 5th ICCD at Kosice,Slovakia 2009;<br>6.Founder,International College of Nutrition,9th World Congress in London,June 24-26,2002,10th WCCN at Phuket,Dec 1-3,2004,12th WCCN,Canada,2006,14th at Kosice,Slovakia 2009;<br>7.Former member,Council on Arteriosclerosis of the World Heart Federation, Switzerland,1990-1998. |

| **PROFILE** | |
|---|---|
| **Switzerland** | **Francois SPERTINI** |
| | francois.spertini@chuv.ch |
| | Chief Physician |
| ***Areas of activity*** | Vaccine, malaria, tuberculosis, immune response, T cells, cytokines |



This event is funded by the Seventh Framework Programme, European Commission

| ORGANISATION | |
|---|---|
| *Name* | Hospice/CHUV |
| *Type* | University, r esearch center |
| *Department* | Division of Immunology and Allergy |
| *Short description* | Hospices/CHUV is a university hospital dedicated to patient care, research and education. Access to outpatient clinics and affiliated laboratories allows the organization of clinical trials as well as preclinical research and development activities to stimulate progresses in our fields of interest, development of vaccine in the field of malaria and tuberculosis. |
| **PROJECT** | |
| *Research project* | ***Development of novel vaccine candidates against malaria and tuberculosis. .***<br>***Openings for other infectious disease candidate vaccines such as hepatitis C.*** |
| *Description of project* | Identification of vaccine candidate antigen in preclinical work in animal. Translational research in Phase I and phase II clinical studies that can be performed in our center then outsourced to endemic areas |
| *Expertise offered* | Strong immunological experiences of follow up of preclinical and clinical trials in the field of vaccination (malaria and tuberculosis). Availability of necessary clinical assay for volunteers follow up. |
| *Requested partner expertise* | Partner with interest for preclinical screening of potentially interesting vaccine candidate that could be tested in phase I/II in healthy/exposed volunteers. |

| PROFILE | |
|---|---|
| **INDIA** | **Padma Srivastava** |
| | vasanthapadma123@gmail.com |
| *Areas of activity* | Professor, Department of Neurology, AIIMS<br>Stroke, Epilepsy, Vascular Dementia |
| **ORGANISATION** | |
| *Name* | AIIMS |
| *Type* | University |
| *Department* | Neurology |
| *Short description* | Top most health center inthe country. Tertiary care and research facility. Multi departmental clinical, teaching, training, research areas. |
| **PROJECT** | |
| *Research project* | ***Comprehensive studies in cerebro-vascular diseases with special reference to Stroke in Young.*** |
| *Short description* | Stroke in young, including stroke in children and young adults (< 45 years) is an important cause of morbidity and mortality throughout the world, especially in developing countries. Despite few studies reported from India on stroke in young, most involved ischemic stroke, conducted before the widespread use of modern neuroimaging methods; and thus with a few exceptions, did not identify stroke subtypes, etiopathogenesis, and long term outcome. India will face an enormous socio-economic |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | burden to meet the costs of stroke in near future. Stroke prevention planning, reliable epidemiological information on pattern of disease and exposure to major risk factors and morbidity or mortality trends for cerebrovascular disease in defined populations is imperative. There is a great need to monitor these trends in a simple and reproducible way. In response to the need for stroke data collection, prevention and treatment, the present project is undertaken, to study, risk factors for stroke in young, including homocysteine, lipoprotein(a), triglycerides and other lipid fractions, procoagulant states, hemoglobin, and infections, assess the impact of stroke prophylaxis on stroke recurrence after first ever stroke in young, and pattern of distribution of atherosclerotic lesions intra-and extra- cranially in stroke in young. The goal is to develop academic/scientific ties between the health professionals and scientists in AIIMS in India and EUtargeting the development of programs in improving understanding of stroke etiopathogenesis, risk factor profiles between the different ethnic communities, awareness, improve risk factor recognition and acute stroke management with focus towards the development of cutting edge tertiary care centers and community programs targeting the population at risk for cerebrovascular disorders with special reference to stroke in young. The data obtained in specifically designed registry will help understand better this unique cohort of patients; the etiopathogenesis, the predisposing risk factors; predilection of sites for atherosclerosis and thus derive at realistic preventative/management protocols specifically designed for stroke in young. Although the idea of a R&D center may be to develop a new technology, it can also be the creation of a "virtual" centre where in like minded investigators across the globe can form a core group to investigate common problems with available resources and not indulge only in high throughput technologies. |
| ***Expertise offered*** | Ranked always as number one hospital and teaching institute in the country continuously for the last decade, it is the country's most premier medical institute. It not only caters to an enormous catchment area of more than 20 million people, it is also the most preferred referral center for the entire country.<br>Stroke services at the institute are part of the department of Neurology, which has a well equipped intensive care, stroke clinic, and comprehensive stroke services catered to by a stroke team. The stroke services include, hyperacute thrombolysis, hyperacute reperfusion therapies, acute interventions, surgery, multimodal stroke neuroimaging, interventions for secondary stroke prevention including angioplasty, stenting etc; stroke clinic and comprehensive rehabilitation services. There are several on going research protocols including stem cells treatment in stroke patients approved by the department of biotechnology (DBT), the Indian Coucnil of Medical Research (ICMR) and the Department of Science and Technology (DST) of government of India. Around 500 to 600 patients are seen every year. Nearly 25% to 30% of these occur in the young (< 45 years). |
| ***Requested partner expertise*** | The goal is to develop academic/scientific ties between the health professionals and scientists in EU and AIIMS in India to develop programs to improve understanding of stroke etiopathogenesis in young (< 45 years), risk factor profiles between different ethnic communities, awareness, improve risk factor recognition and acute stroke management with focus towards the development of cutting edge tertiary care centers and community programs targeting the population at risk for cerebrovascular disorders with special reference to stroke in young. |

| **PROFILE** | |
|---|---|
| **UK** | **MICHAEL STEWART** |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | m.g.stewart@open.ac.uk |
| | Prof of NEUROSCIENCE |
| *Areas of activity* | NEUROSCIENCE, COGNITION, MEMORY |
| **ORGANISATION** | |
| *Name* | THE OPEN UNIVERSITY |
| *Type* | University |
| *Department* | LIFE SCIENCES |
| *Short description* | UNIVERSITY WITH 200,000 students |
| **PROJECT** | |
| *Research project* | ***NEURODEGENERATION AND AGEING IN THE CENTRAL NERVOUS SYSTEM*** |
| *Description of project* | My main recent research activities have been concerned with investigating correlates of experiential and disease-induced changes in the mammalian CNS, both in vivo and ex vivo. |
| *Expertise offered* | My research utilises microscopical imaging methods for morphometrical analysis of neural circuitry as well as quantification of immediate early gene expression in order to determine the precise localisation of age and disease related changes in the hippocampus |
| *Requested partner expertise* | Expertise in CNS strcuture and cellular neuroscience |

| | |
|---|---|
| **PROFILE** | |
| **Bulgaria** | **Desislava Stoilova** |
| | stopfak@swu.bg |
| | Ass.Professor |
| *Areas of activity* | Occupational Health and Safety, Economics, Finance |
| **ORGANISATION** | |
| *Name* | South-West University "Neofit Rilski", Faculty of Economics |
| *Type* | University |
| *Department* | Faculty of Economics |
| *Short description* | The Faculty of Economics at the South-West University was founded in the autumn of 1991 and was among the first accredited faculties of economics in Bulgaria. Since its establishment the basic priorities of the Faculty of Economics have been the development and modernization of teaching and research. Over the past few years the faculty has become a recognized academic and research unit. A large number of full-time and part-time lecturers of national renown, prominent experts in finance, macroeconomics, management, trade, bank and financial law were attracted to work for the faculty.<br>For all these reasons, "Blagoevgrad School of Economics" is expected to win recognition in the training in Finance, Tourism, Management, and Economics of the Social and Cultural Sphere. These are the priority degree programs of the faculty which hold much |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | promise to make a vigorous breakthrough in the education market in Bulgaria by means of qualitative training in the accredited Bachelor's, Master's and Doctor's programs. All degree programs of Economics have traditionally occupied good positions at the university and they are one of the most preferred programs by the candidate students. |
| **PROJECT** | |
| ***Research project*** | ***Building a Knowledge Repository for Occupational Well-being Economics Research*** |
| ***Description of project*** | The project aims to settle the fundamental basis that will enhance research on Occupational Health and Safety (OHS) Economics, which will allow for the development of policies regarding this issue. This goal will be achieved through a Coordination Action which will bring together the leading OHS Economists in Europe. Their knowledge will be gathered through literature reviews, meetings and conferences and made available to the community through a dynamic on-line repository which will contain OHS Economics issues and will allow for discussion and communication of principles, case studies and handy management (accounting) tools. Two specialised Working Group (WinG) meetings focusing on OHS Macroeconomics and OHS Microeconomics, respectively and two conferences on OHS Economics will attract new contributions in order to assess the impact of changing conditions of economy and labour on OHS. |
| ***Expertise offered*** | Expertise in the scope of finance, economics, management, occupational health and safety. |
| ***Requested partner expertise*** | It depends on the project objectives. |

| | |
|---|---|
| **PROFILE** | |
| **France** | **Jamal Tazi** |
| | jamal.tazi@igmm.cnrs.fr |
| | Professor at University<br>Director of Splicos Therapeutics lab |
| ***Areas of activity*** | Pharmacology, HIV, Cancer, Splicing |
| **ORGANISATION** | |
| ***Name*** | IGMM-CNRS University of Montpellier II |
| ***Type*** | SME- University |
| ***Department*** | Biochemistry and physiology |
| ***Short description*** | Splicos Therapeutics is new cooperative laboratory is created jointly between Splicos, CNRS, INSERM and the Universities of Montpellier I and II. It is intended to give a strong impetus to the drug discovery endeavour of the teams headed by Pierre ROUX (CRBM) and Jamal TAZI (IGMM) and to bring it to the point where they can match the requirements of pharmaceutical research. This additional effort would also provide a good return to basic science inasmuch as candidate drugs are valuable tools to further explore cellular mechanisms like splicing, viral replication or cancer metastasis. This new laboratory will exploit the first discoveries stemming from research by these two teams on alternate splicing as a potential target for new therapies against cancer, viral diseases or genetic disorders. |



This event is funded by the Seventh Framework Programme, European Commission

| PROJECT | |
|---|---|
| *Research project* | ***targeting the splicing machinery for the development of new chemicals with therapeutic potential*** |
| *Description of project* | Our group is interested in two crucial steps for the control of gene expression. The first one is alternative splicing which is responsible for the protein diversity required for the development of higher organisms and also for many pathological dysfunctions (genetic diseases, cancer…), offering a completely original target for the development of new chemicals with therapeutic potential. The second is the selective degradation of particular messengers allowing for a fine tuning of both the level and the timed expression of some genes. |
| *Expertise offered* | Gene expression, mRNA metabolism, HIV replication, Cancer, genetic rare diseases |
| *Requested partner expertise* | Bioinformatics, Chemistry |

| PROFILE | |
|---|---|
| The Netherlands | **Jelle Thole** |
| | jelle.thole@wur.nl |
| | Director |
| *Areas of activity* | Tuberculosis, Vaccines, Biomarkers, Development, Partnership |
| **ORGANISATION** | |
| *Name* | TuBerculosis Vaccine Initiative (TBVI) |
| *Department* | Other |
| *Short description* | TuBerculosis Vaccine Initiative (TBVI) is an indepent nonprofit foundation that stimulates integrated European efforts to develop more effective, safe vaccines against tuberculosis, that will be globally accessible and affordable. TBVI descends from TBVAC, an EU Framework Program 6 integrated project, which has been highly successful in advancing a portfolio of new tuberculosis vaccines through preclinical and early clinical development stages. TBVI is a mainly European network that includes the best (almost 40) research institutes and universities in the field of tuberculosis research.<br>The objectives of TBVI are:<br>• Stimulate research and discovery on TB vaccines<br>• Assure preclinical and early phase clinical development<br>• Guarantee that promising projects result in affordable vaccines as soon as possible<br>• Develop biomarkers that will increase performance and speed of vaccine development<br>• Increase capacity of existing clinical trial sites in developing countries<br>• Raise political and public awareness on the global health threat of TB and the need for new vaccines |
| **PROJECT** | |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Research project*** | ***Discovery and preclinical testing of new vaccine candidates for tuberculosis*** |
| ***Description of project*** | With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current control measures the Millennium Development Goals (MDGs) set for 2015 may be achieved, reaching these would still leave a million people per year dying from TB. Much more effective measures, particularly more effective vaccines will be essential to reach the target of eliminating TB in 2050. Two successive FP5 and FP6 funded projects, Tuberculosis (TB) Vaccine Cluster (2000-2003) and TBVAC (2004-2008), have in the recent decade made significant contributions to the global TB vaccine pipeline, with four vaccines (out of nine globally) being advanced to clinical stages. Both projects strongly contributed to the strengthening and integration of expertise and led to a European focus of excellence that is unique in the area of TB vaccine development. In order to sustain and accelerate the TB vaccine developments and unique integrated excellence of TBVAC, a specific legal entity was created named TuBerculosis Vaccine Initiative (TBVI). The NEWTBVAC proposal is the FP7 successor of TBVAC, and will be coordinated by TBVI. The proposal has the following objectives : 1) To sustain and innovate the current European pipeline with new vaccine discoveries and advance promising candidates to clinical stages; 2) To design new, second generation vaccines based new prime-boost strategies and/or new (combinations of) promising subunit vaccines, that will impact on reduction of disease in exposed individuals; 3) To sustain and innovate discovery, evaluation and testing of new biomarkers, that will be critically important for future monitoring of clinical trials.<br><br>Expected results: • Second generation vaccine candidates that either alone or in combination with existing candidates, may replace or boost BCG and be more effective against primary (pulmonary) TB, and/or may reduce development of disease in exposed individuals.• New innovate candidate biomarkers, that will be critically important for future monitoring of clinical trials, and reducing time and resources for clinical trials sites |
| ***Expertise offered*** | A network of over 40 mainly Europena Partners with unique and excellent knowledge and know how in vaccine discovery, perclinical and non clinical development, and early clinical trial expertise |
| ***Requested partner expertise*** | Clinical trials capacity to test new tuberculosis vaccine candidates in early phase I and II clinical trials in an endemic setting |

| **PROFILE** | |
|---|---|
| **FRANCE** | **Laszlo TORA** |
| | laszlo@igbmc.u-strasbg.fr |
| | Research Director (DR1) at CNRS; Group Leader, |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Areas of activity*** | Molecular biology, LS1, Gene expression, genome wide, regulation, mammalian cells, chromatin, RNA Polymerase II, transcription, histone acetyl transferase complexes, cancer. |
| **ORGANISATION** | |
| ***Name*** | Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) UMR 7104 CNRS, UdS, INSERM U964 |
| ***Type*** | Research center |
| ***Department*** | Functional Genomics |
| ***Short description*** | The IGBMC is an internationally recognised research centre that hosts a number of interdisciplinary research groups with an excellent track working on aspects of regulation of transcription, chromatin biology and development using various model systems. The IGBMC, which is a mixed research unit CNRS/Inserm/Université De Strasbourg of approximately 600 people, in 44 research groups including 300 researchers, post-doctoral fellows and PhD students and is structured in 5 departments, which in turn are supported by 5 technological platforms, and 12 highly developed common facilities, occupies an eminent position in the landscape of biological and medical research in France, both due to its unique structure and its research of international reputation (FP6: 37 contracts, €20M in receipts).<br>The current activities of the IGBMC, Strasbourg, cover a spectrum of disciplines in cell- and molecular biology as well as biophysics and developmental biology. Almost 600 scientists from 47 different nations are working in about 44 teams on the following issues:<br>-Regulation of basal and activated RNA polymerase II transcription;<br>-Biochemistry, genetics and molecular biology of nuclear receptors;<br>-Structure determination of proteins and nucleic acids;<br>-Biology and molecular genetics of different cancers;<br>-Human molecular genetics;<br>-Developmental and molecular biology of C. elegans, Drosophila, zebrafish and mouse;<br>-Neurobiology<br>Resources made available to the groups;<br>-DNA sequencing (high throughput sequencing will be available from 2009)<br>-peptide synthesis, MALDI-TOFF mass spectrometry,<br>-poly- and monoclonal antibody facilities and services,<br>- cell culture facilities and services,<br>-baculovirus overexpression service,<br>-transgenic animals, ES cell facility,<br>-crystallography, X-ray defraction, NMR, electromicroscopy,<br>-imaging platform,<br>-transcriptome platform,<br>-FACs analysis service,<br>-bioinformatics platform. |
| **PROJECT** | |
| ***Research project*** | ***Functional and genome wide characterization of histone acetyl transferase complexes in normal and cancer cells*** |
| ***Short description*** | Transcription in eukaryotes is a tightly regulated, multistep process. Gene specific transcriptional activators, several different cofactors, often harbouring chromatin modifying activities, and general transcription factors are necessary to access specific loci in the chromatin to allow precise initiation of RNA polymerase II transcription. Post-translational modifications of histones have been correlated with the involvement of the chromatin in transcription activation or repression. One of the most extensively |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | studied modifications is the acetylation of the highly conserved amino-terminal histone tails. Histone acetyl transferases (HATs) are thought to increase the decompaction of chromatin, which in turn increases the accessibility of factors that promote transcription.<br>One of the most appealing questions in eukaryotic transcription is how activators can transmit their signals to the general transcription machinery to stimulate transcription in the context of a highly condensed chromatin environment. Another exciting question from the eukaryotic transcription regulation point of view is how stem cells can regulate their transcription networks to maintain their pluripotency and how these regulatory networks change when stem cells differentiate to various cell types. Stem cells have recently become the focus of intensive research, because they may be used in the future to generate cells and tissues for therapeutic purposes.<br>Since their identification, many studies have been carried on the structure, role and function of different HAT complexes in yeast, however relatively little is know about the role and function of these complexes in metazoans and how these chromatin modifying complexes are involved in maintenance of pluripotency and differentiation. In the previous years we have devoted our efforts to the characterization of the human SAGA-type (GCN5- or PCAF-containing) complexes. However, in the past year others and we have discovered a novel GCN5- or PCAF-containing complex, called ATAC (for Ada two a containing). We hypothesize that the increased complexity of GCN5- or PCAF-containing HAT complexes in metazoans, as compared to yeast, is required for metazoan specific functions such as cell pluripotency and differentiation. To better understand the function of the GCN5- or PCAF-containing HAT complexes in metazoans and begin to answer the above exposed two fundamental questions together, in our present project we propose:<br>-to perform the biochemical and cellular characterization of SAGA and ATAC complexes in normal and cancer cells by using proteomics to identify a) the subunit composition of these complexes b) the normal and cancer cell interactome of ATAC and SAGA (GCN5- or PCAF-containing) c) the post-translational modifications of the identified subunits<br>-to identify direct ATAC and SAGA binding sites in the genome of normal and cancer cells by using chromatin immunoprecipiattion coupled high throughput sequencing (ChIP-seq) and bioinformatics<br>-to identify ATAC and SAGA target genes and their role in normal and cancer cells and differentiation by using knockdown approaches coupled to global transcriptomic analyses<br>-to identify deregulated pathways, networks and hubs regulated by the ATAC or SAGA HAT complexes in cancer cells, by using high throughput and newly developed bioinformatics techniques, tools and platforms.<br>The present project will be built on the combined strengths of the partners, including molecular biology, chromatin, cancer biology, systems biology, genome research and bioinformatics. |
| ***Expertise offered*** | Molecular biology, chromatin, cell biology |
| ***Requested partner expertise*** | Cancer biology, genome research and bioinformatics. |

| **PROFILE** | |
|---|---|
| **United Kingdom** | **W. Bruce TRAILL** |
| | w.b.traill@reading.ac.uk |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | Project Leader for Eatwell project |
| **ORGANISATION** | |
| ***Name*** | University of Reading |
| ***Type*** | University |
| ***Department*** | School of Agriculture, Policy and Development |
| ***Short description*** | The University of Reading is ranked as one of the UK's 10 most research-intensive universities and as one of the top 200 universities in the world. We enjoy a world-class reputation for teaching, research and enterprise. The quality and diversity of our research is recognised nationally and internationally, with a number of our researchers receiving awards for their work. We are home to several centres of excellence and conduct world-class research across a broad range of disciplines. The Research Assessment Exercise (RAE) 2008 results confirm the standing of the University of Reading as a research-intensive university. Published in December 2008, the outcomes recognise over 87% of the university's research to be of international standing. The work of over 600 University of Reading research active staff was submitted to the Higher Education Funding Council for England for the RAE (88% of our eligible staff), demonstrating the breadth and quality of research across the university. |
| **PROJECT** | |
| ***Research project*** | ***Interventions to Promote Healthy Eating Habits: Evaluation and Recommendations*** |
| ***Description of project*** | Obesity is a major concern in Europe, with an increasing health and economic burden. Obesity has been estimated to cost the EU some €70 billion annually through health care costs and lost productivity, and additionally over-consumption of salt, sugar and saturated fats and under-consumption of fruit and vegetables cause almost 70,000 premature deaths annually in the UK alone. Member states have initiated a variety of policy interventions to encourage healthy eating, including prohibitions on advertising certain foods to children, promotion of fruit and vegetable consumption, nutrition labelling, dialogue with food industry to improve food product composition and regulation of school meals and public sector canteens to ensure healthy food offerings. Rarely have these been evaluated in a systematic manner.<br>Thus, the objectives of this project are as follows:<br>• Assessment of the efficacy of past interventions in improving dietary and health outcomes, and identification of promising avenues for the future<br>• Assessment of the acceptability of potential future interventions and generation of best-practice guidelines for implementation<br>• Provision of policy, data collection and monitoring advice in relation to healthy eating<br>• Management of project to optimise scientific output and communication of scientific findings to a wide audience |
| ***Expertise offered*** | Economics and policy in relation to diet and health |

| | |
|---|---|
| **PROFILE** | |
| **BELGIUM** | **Professor Jan TYTGAT** |
| | jan.tytgat@pharm.kuleuven.be |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | Full Professor, Head of the Laboratory of Toxicology and Food Chemistry<br>Director of Leuven Research & Development Biopharmaceutical Science Division |
| ***Areas of activity*** | Drug discovery, biodiversity, lead compounds, screening tools, biotechnology |
| **ORGANISATION** | |
| ***Name*** | Catholic University of Leuven (K.U.Leuven) |
| ***Type*** | University |
| ***Department*** | Farmaceutical Sciences – Laboratory of Toxicology & Food Chemistry |
| ***Short description*** | K.U.Leuven is one of the main universities in Belgium for higher education with approx. 30,000 students and an affiliated university hospital (UZ Leuven).<br>The laboratory of toxicology and food chemistry is involved in tuition, research and consultancy of substances that may become toxic, including food safety, with an emphasis on the negative effect of these substances on human health and environment. |
| **PROJECT** | |
| ***Research project*** | ***Exploring India's traditional biodiversity for state-of-the-art drug discovery*** |
| ***Short description*** | Numerous examples of drugs currently being used in medicine have demonstrated the innovative potential of natural products and their impact on drug discovery. By exploring biodiversity and discovering interesting substances called 'lead compounds', nature has indeed provided mankind with new therapeutic approaches and an unraveling of important biochemical or physiological pathways.<br>The proposed project wants to explore India's traditional biodiversity, particularly in the field of marine organisms, in order to discover novel generations of drugs (e.g. analgesics, antibiotics, immunosuppressants) that will benefit the entire population worldwide. As such, this project also contains an important element of valorization. |
| ***Expertise offered*** | State-of-the-art biotechnological, analytical approaches & techniques (chromatographic techniques coupled to mass spectrometry, recombinant synthesis and purification of peptides, cDNA and genomic cloning of organisms), combined with a semi-high throughput bioassay screening on a wide array of membrane-bound target (i.e. electrophysiological techniques investigating ion channels and receptors) |
| ***Requested partner expertise*** | Knowledge in biodiversity and its traditional medical use, plus skills in collecting the (start) material. |

| | |
|---|---|
| **PROFILE** | |
| **UK** | **Pankaj Vadgama** |
| | p.vadgama@qmul.ac.uk |
| | Director, Interdisciplinary Research Center in Biomedical Materials |
| ***Areas of activity*** | biosensors; membrane technology; diabetes |



This event is funded by the Seventh Framework Programme, European Commission

| ORGANISATION | |
|---|---|
| *Name* | Queen Mary University of London |
| *Type* | University |
| *Department* | Interdisciplinary Research Center in Biomedical Materials |
| *Short description* | Queen Mary is the third largest College in the University of London, and has both Science/Engineering and Medical Faculties. The Interdisciplinary Research Center (IRC) is housed in the School of Engineering and Materials Sciences ad has a range of programmes focussing on implant materials (bioceramics, dental materials, bone and joint replacement, tissue engineering); there is also an active research programme on biosensors for clinical use. |
| **PROJECT** | |
| *Research project* | ***Biocompatible in vivo sensors for calibration free glucose monitoring in diabetes*** |
| *Description of project* | Electrochemical biosensors based on classical oxidase enzyme reaction chamistry will be developed, but with specific attention to their materials components in order to overcome the effets of adverse tissue and blood reactions affecting device performance. The unique aspect of the project will be to establish a microfluidic interface to further augment device stability in vivo. |
| *Expertise offered* | Polymeric membrane technology for packaging biosensors and electronic devices; microfluidic design for in vivo use; biosensor response modelling |
| *Requested partner expertise* | Animal models, microfabrication; electronic signal processing, wireless transmission, biomolecule immobilisation, thick film deposition |

| PROFILE | |
|---|---|
| Belgium | **Wim VandenBerghe** |
| | wim.vandenberghe@ua.ac.be<br>w.vandenberghe@ugent.be |
| | Professor Doctor |
| *Areas of activity* | NFkappaB, epigenetics, inflammation, cancer, cardiovascular disease |
| **ORGANISATION** | |
| *Name* | Lab Protein Science, Proteomics & Signaling, University Antwerp / University Ghent |
| *Type* | University |
| *Department* | Biomedical Sciences |
| *Short description* | Study of epigenetic programming of inflammation. Controlled inducible expression of inflammation responsive genes is essential during immune responses and immune homeostasis. In contrast, deregulated chronic inflammatory conditions in various cell types frequently result in cancer, cardiovascular or neurological disease. Selectivity, strength and time dependency of gene expression largely depends on activation and interaction of transcription factors/cofactors (i.e. NFkB, AP1, Sp1, HDAC, HMT, dnmt, etc.) and their posttranslational modifications with the chromatin environment. Furthermore, chromatin regulation (nucleosome dynamics, histone modifications), |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | noncoding RNAs and epigenetic modifications (DNA methylation of CpG motifs) integrate various input signals (infection, inflammation, stress, metabolism, nutrition) which are ultimately recorded and imprinted into the epigenome.<br>Identifying specific protein interactions and signaling functions in relation to epigenetic marks in in different in vitro/ in vivo cell models, representative for cancer, cardiovascular or neuroimmunological disease, is an absolute requirement for translational approaches aiming at identifying small inhibitor molecules (for example derived from medicinal plants) for preventive or therapeutic applications. |
| **PROJECT** | |
| ***Research project*** | ***Optimised delivery of Ayurvedic functional food for improved cardiometabolic health and reduced cardiovascular risk*** |
| ***Description of project*** | Cardiometabolic disease includes a wide range of risk factors leading to vascular damage. Cardiovascular disease remains to be among the foremost causes of deaths worldwide and statistics about this condition is quite alarming. Despite steadily improving patient care,cardiovascular disease continues to grow to epidemic proportions, with the continued prevalence of a variety of risk factors including dyslipidemia, diabetes, obesity, hyperhomocysteinemia and arterial damage. Nutrition, i.e. our daily diet, is a major life style factor, greatly impacting on cardiometabolic disease. Today, there is growing interest in the composition of manufactured foods and the role that reformulation can play in making our diets healthier. Ayurveda, one of the ancient systems of health care of Indian origin, requires rediscovery in light of our current knowledge of allopathic (modern) medicine for the therapeutic and preventive purpose. Roughly translated into "Knowledge of life", it is based on the use of natural herbs and herb products for therapeutic measures depending on synergistic health beneficial effects of all compounds present in a given formulation. Ayurvedic extracts are used in several indigenous preparations (food supplements, tonics, drugs) for maintaining health as well as treatment of several disease conditions, including cardiometabolic disease. CARDIYURVEDA, aims at:(1) identifying synergistic cardioprotective formulations of Ayurvedic bioactives with turmeric and their metabolites; (2) investigating key parameters of bioavailability upon gastrointestinal simulation towards surrogate markers of cardiovascular function in vitro/vivo; (3) developing innovative, functional, and nutritionally responsible food matricesfor optimised dietary delivery of Ayurvedic formulations; (4) demonstrating cardiovascular benefits and safety of Ayurvedic food products (5) exchanging know-how between India (ayurveda) and Europe (allopathy) through a dedicated training programme |
| ***Expertise offered*** | Molecular Cell Biology, Epigenetics, Chromatin Biology, Gene Expression, Kinase signaling, NFkappaB, Hormone receptor biology, Herbal Compound purification, inflammation, cancer, cardiovascular disease |
| ***Requested partner expertise*** | Ayurvedic medicine - Ayurvedic herbs - Herbal formulations |

| | |
|---|---|
| **PROFILE** | |
| **The Netherlands** | **Lia van der Hoek** |
| | c.m.vanderhoek@amc.uva.nl |
| | Associate professor |
| ***Areas of activity*** | Respiratory viruses, virus discovery, coronavirus, parvovirus, HIV-1, RSV, parechoviruses, influenzavirus |



This event is funded by the Seventh Framework Programme, European Commission

| ORGANISATION | |
|---|---|
| *Name* | University of Amsterdam, Academic Medical Center |
| *Type* | University |
| *Department* | Medical Microbiology, Experimental Virology |
| *Short description* | I run a unit that works on virus discovery and respiratory viruses, in particular coronavirus NL63 (which we discovered in 2004), influenzavirus (swd-H1N1) and human bocavirus type 1 (culture system, 2009) |
| **PROJECT** | |
| *Research project* | ***Response to an outbreak: virus identification and virus culture in human airway epithelial cultures*** |
| *Description of project* | Unknown viruses can be identified by relatively simple PCR-based amplification techniques. Unfortunately, a culture system is often lacking for these "new" viruses. We published that differentiated cell cultures provide a culture system for these viruses (J Virol. 2009 Aug;83(15):7739-48), thus antivirals can be tested. |
| *Expertise offered* | Large experience in sequence independent amplifcation of unknown viruses (Nat Med. 2004 Apr;10(4):368-73) and primary differentiated cell cultures for virus discovery |
| *Requested partner expertise* | Outbreak management teams |

| PROFILE | |
|---|---|
| **Hungary** | **László Vécsei** |
| | vecsei@nepsy.szote.u-szeged.hu |
| | Director, Department of Neurology |
| *Areas of activity* | neurodegeneration, kynurenines, multiple sclerosis, headache, Parkinson's disease, stroke, polyneuropathy |
| **ORGANISATION** | |
| *Name* | University of Szeged, Department of Neurology |
| *Type* | University |
| *Department* | Department of Neurology |
| *Short description* | Our Department of Neurology has 60 active and 40 rehabilitation beds with large outpatient activities. We have reserach projects in the field of clinical and experimental neurology (see: PUBMED, Web of Sciences) |
| **PROJECT** | |
| *Research project* | ***Biomarkers of neurological disorders: neurodegeneration and neuroprotection***. |
| *Description of project* | The role of novel kynurenine and kynurenic acid analogues in the treatment of neurological disorders. We investigate newly synthesized neuroprotective molecules in different experimental models of neurological disorders. Furthermore, we measure |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | biomarkers of neurological disorders. |
| ***Expertise offered*** | immunohistochemistry, behavioral pharmacology HPLC, |
| ***Requested partner expertise*** | depending from the future joint project |

| **PROFILE** | |
|---|---|
| **SPAIN** | **Sabino VEINTEMILLAS-VERDAGUER** |
| | sabino@icmm.csic.es |
| | RESEARCHER |
| ***Areas of activity*** | MAGNETIC NANOPARTICLES, CONTRAST AGENTS FOR MRI |
| **ORGANISATION** | |
| ***Name*** | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS |
| ***Type*** | Research center |
| ***Department*** | INSTITUTO DE CIENCIA DE MATERIALES DE MADRID |
| ***Short description*** | BASIC AND APPLIED RESEARCH |
| **PROJECT** | |
| ***Research project*** | ***PREPARATION OF AQUEOUS MAGNETIC DISPERSIONS FROM NANOCOMPOSITE NANOPARTICLES*** |
| ***Description of project*** | The main objective of the project is the development of new magnetic colloids with improved magnetic response or multiple functionality with the intention of being imaged by several techniques. |
| ***Expertise offered*** | Synthesis, characterization of nanomaterials by non standard techniques (organic decomposition and laser pyrolysis) and preparaiton of biocompatible dispersions with them. |
| ***Requested partner expertise*** | Toxicity of nanomaterials in general sense |

| **PROFILE** | |
|---|---|
| **Hungary** | **Beata Vertessy** |
| | vertessy@enzim.hu |
| | Scientific Advisor (University equivalent: Full Professor) |
| ***Areas of activity*** | DNA repair, apoptosis, pathogenic microorganisms, drug development |
| **ORGANISATION** | |
| ***Name*** | Institute of Enzymology, Hung. Academy of Sciences |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| ***Type*** | Research center |
| ***Department*** | Laboratory of Genome Metabolism and Research |
| ***Short description*** | Academic research institute, EU Center of Excellence |
| **PROJECT** | |
| ***Research project*** | ***Novel targets against Mycobacterium tuberculosis and Plasmodium falciparum*** |
| ***Description of project*** | Identification of novel key protein targets in the metabolic and protein-protein interaction network of major pathogens, with special focus on the casuative agents of tuberculosis and malaria. Key reference: Vertessy, B.G. Accounts in Chemical Research, 2009 Jan 20;42(1):97-106 |
| ***Expertise offered*** | spectroscopic and thermodynamic techniques, X-ray crystallography, human and insect cell laboratory |
| ***Requested partner expertise*** | testing in Mycobacterium tuberculosis and in Plasmodium species |

| | |
|---|---|
| **PROFILE** | |
| **UK** | **Paul Wallace** |
| | info@qcmd.org |
| | QCMD Executive |
| ***Areas of activity*** | Quality Assurance, Quality Control, External Quality Assessment, Proficiency testing, laboratory assessment, molecular diagnostics, infectious diseases |
| **ORGANISATION** | |
| ***Name*** | Quality Control for Molecular Diagnostics (QCMD) |
| ***Type*** | Other |
| ***Short description*** | Quality Control for Molecular Diagnostics (QCMD) is a non commercial organization which specializes in the management and provision of External Quality Assessment programmes for molecular diagnostics. QCMD was established as a result of an International concerted action programme focused on improving the quality of clinical laboratory molecular diagnostics through proficiency testing. QCMD is fully endorsed by the European Society for Clinical Virology (ESCV), the European Society for Microbiology and Infectious Disease (ESCMID) and other international scientific societies. It also maintains close working relations with key International bodies including the WHO and is supported by a Scientific Advisory Board (SAB), whose members are recognised international experts in Infectious disease and molecular diagnostics. In addition, QCMD maintains a close professional relationship with the major diagnostic test manufacturers through the Industrial Liaison Committee (ILC).<br>QCMD's primary focus is infectious diseases and the organization is responsible for the management and distribution of programmes to over sixty countries with over 3,000 programme registrations per annum. The programmes are designed by experts and offer a wide range of challenges, such as target types, sensitivity, specificity etc. QCMD is an ISO 9001:2000 certified organization and the programmes are conducted following |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | a clear 'code of practice' which is based on current guidelines (ISO/IEC Guide 43-1, ILAC-G13-2000 and prEN 14136:2001). |
| ***PROJECT*** | |
| ***Research project*** | ***Establishment of a quality network for molecular diagnostics within infectious diseases*** |
| ***Description of project*** | Expansion of the EQA programmes and Implementation and trial of a novel 'on-line' internal QC programme for monitoring the performance on a daily basis.<br>The preparation of further publications relating to the quality programmes.<br>The further development and coordination of existing and future QC programmes.<br>The alignment of the EQA / PT schemes with the regional accreditation / certification requirements.<br>Establishment of new molecular diagnostic methods and protocols. This will be through the provision of defined protocols in specific project areas (e.g. viral Genotyping). |
| ***Expertise offered*** | Molecular, Information technology, statistics,infectiuos diseases |
| ***Requested partner expertise*** | Local infectious disease experts<br>The collaboration provides active research links to the major scientific societies |

| | |
|---|---|
| **PROFILE** | |
| **Spain** | **Kenneth Weissmahr** |
| | advancell@advancell.net |
| | CEO |
| ***Areas of activity*** | cell-based reagent; in vitro; research, nanotechnology, nanosystems, oncology, veterinary, therapeutics, drug.delivery, bioavailability. |
| **ORGANISATION** | |
| ***Name*** | ADVANCELL Advanced in vitro Cell Technologies, S.A. |
| ***Type*** | Other |
| ***Short description*** | Advancell is a biotechnology company with its own technology and continuous innovation; it deals with unresolved questions in health and wellbeing using value-adding, efficient products and services. The company thrives on its discoveries from the academic environment and improving, developing and licensing them to third parties or launching them on the market.<br>The company is organized into three business Units:<br>Advancell Alternative Testing, helps to improve the development process of new products in biotech, pharmaceutical, cosmetics and chemical industry by providing research services and cell-based in vitro models for prediction of safety, efficacy and the mechanism of action of molecules under development.<br>Advancell Nanosystems, uses natural polymer Nanosystems to improve the delivery and administration of drugs and modulate their bioavailability in oral, nasal and topical applications<br>Advancell Therapeutics, focuses its activity on the development of new drugs based on discoveries by the academic world with a strategy of the efficient use of resources to achieve the clinical trial stage and license to third parties for marketing and sales |



This event is funded by the Seventh Framework Programme, European Commission

| PROJECT | |
|---|---|
| *Description of project* | Development of prototypes using proprietary Nanosystems technology. Current pipeline:<br>- Oral application of Insulin<br>- Oral application of Heparine<br>- mucosal administration of nucleic acids (DNA and siRNA) for gene therapy<br><br>Pharmaceutical developments up to clinical proof of concept.<br>Current pipeline:<br>ATH001 - Acadra® for the treatment of B-cell, Chronic Lymphocytic leukemia.<br>ATH008 – for topical treatment of Palmar Plantar Eytrodysetesia.<br>ATH004 Cyclostopic-Vet® for the topical treatment of atopic dermatitis in dogs |

| PROFILE | |
|---|---|
| **UK** | **Dirk Werling** |
| | jelliott@rvc.ac.uk |
| | Professor of Molecular Immunology |
| *Areas of activity* | Innate immune system of farm-animals |
| **ORGANISATION** | |
| *Name* | Royal Veterinary College, University of London |
| *Type* | University |
| *Department* | Research Division |
| *Short description* | The RVC is the oldest, largest and only self-governing Veterinary School in the UK. Our mission is to improve the health and welfare of animals. We undertake research of international quality as recognised by our outstanding performance in the recent UK Government run Research Assessment Exercise (90% of our research was categorised as being of international standard). Infection and Immunity research is an area of particular excellence and we integrate lab based scientists with whole animal research and research at the population level. We work on endemic, emerging and exotic disease, particularly those of zoonotic potential and are particularly keen to work with international partners. |
| **PROJECT** | |
| *Research project* | ***Targetting the innate immune system of farm-animals for vaccine improvement*** |
| *Description of project* | The main area of research is the innate immune system, and the main questions the group is trying to answer concern how viruses can circumvent the innate immune system and how one can prime the innate immune-system to obtain a specific adaptive immune response. This aspect of the work has recently attracted interest from pharmaceutical companies.<br>Current research focuses on recent evidence that there are species differences in the innate immune system and how this may affect vaccine designs. Current vaccine formulations are based on experiences in the mouse or human system, and the groups research is trying to assess whether these vaccines/vaccine-adjuvants are the ideal |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | formulation for use in other domestic species.. |
| ***Expertise offered*** | Measuring immune responses in a variety of in vivo/in vitro systems |
| ***Requested partner expertise*** | Purification and synthesis of glycoproteins/glycolipids.. |

| **PROFILE** | |
|---|---|
| **United Kingdom** | **Martin Woodward** |
| | Wybridge@vla.defra.gsi.gov..uk |
| | Head of Department for Food and Environmental Safety |
| ***Areas of activity*** | Molecular diagnostics; disease consultancy; surveillance; pathogenesis and control research |
| **ORGANISATION** | |
| ***Name*** | Veterinary Laboratories Agency UK |
| ***Type*** | Research center |
| ***Short description*** | Veterinary surveillance and Research. Primary focus on the control of zoonoses and detection and elimination of emergent infections in animals. |
| **PROJECT** | |
| ***Expertise offered*** | Massively parallel DNA sequencing; MS technology: Biolog mass phenotyping; imaging (confocal, LDM etc); vaccine development; animal testing facilities; expert consultancy; array technology; molecualr diagnostics (various platforms). |

| **PROFILE** | |
|---|---|
| **France** | **Bigot Yves** |
| | yves.bigot@univ-tours.fr |
| | Head of GICC, CNRS Research Director |
| ***Areas of activity*** | Non-viral vectorology, Immunotherapy, tumor instability, organic synthesis of inhibitor |
| **ORGANISATION** | |
| ***Name*** | Génétique Immunothérapie, Chimie et Cancer - UMR CNRS 6239 |
| ***Type*** | University |
| ***Department*** | UFR des Sciences et Techniques |
| ***Short description*** | A lab presentation is available at : http://gicc.univ-tours.fr/laboratoire/presentation/index.php?connect=0&lang=en |
| **PROJECT** | |
| ***Research project*** | ***Engineering transposon vectors for gene delivery purposes*** |
| ***Description of project*** | The aim of our project is to engineer transposon vectors to make a tool box of vectors for gene delivery purposes (gene therapy, bioproduction, fabrication of sensor animals). |



This event is funded by the Seventh Framework Programme, European Commission

| | |
|---|---|
| | Vectors are enginered to be insertion site specific into Telomers pr rRNA genes, non silenced and/or to have interesting cargo capacties. |
| ***Expertise offered*** | Vector choice and design depending on the prupose |
| ***Requested partner expertise*** | Ex vivo gene therapy, bioproduction (quality of biosimilar products) and/or sensor animals |

| **PROFILE** | |
|---|---|
| **Italy** | **Donato Zipeto** |
| | donato.zipeto@univr.it |
| | Assistant Professor |
| ***Areas of activity*** | HIV-1 vaccine research, HIV-1 basic research |
| **ORGANISATION** | |
| ***Name*** | University of Verona |
| ***Type*** | University |
| ***Department*** | Dipartimento Materno Infantile e di Biologia Genetica |
| **PROJECT** | |
| ***Research project*** | ***New immunogens for the induction of broad spectrum neutralizing antibodies against HIV-1*** |
| ***Description of project*** | Analysis of the immunogenicity of new antigens (fusion complexes, CD4-independent env, Env/HLA-C complexes), isolation and characterization of broad specrum neuralizing antibodies against HIV-1 |
| ***Expertise offered*** | Molecular Biology, Cellular Biology, Retrovirology, Viral vectors, pseudoviruses, confocal microscopy |
| ***Requested partner expertise*** | Immunology, monoclonal antibodies, etc. |



This event is funded by the Seventh Framework Programme, European Commission